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The prion protein (PrPC) is a cell surface glycoprotein that binds Cu2+ ions. The misfolding and oligomerisation of PrPC is responsible for a range of transmissible spongiform encephalopathies (TSEs) in mammals. As changes in PrPC conformation are intimately linked with disease pathogenesis, the effect of Cu2+ ions on the structure and stability of PrPC has been investigated. 
In chapter 3, urea unfolding studies indicate that Cu2+ ions destabilise the native fold of PrPC. The mid-point of the unfolding transition is reduced by 0.73 ± 0.05 M urea in the presence of Cu2+ ions equating to an appreciable difference in free energy of unfolding (∆∆GU[D]50%), 2.02 ± 0.05 kJmol-1. This suggests that in Prion diseases, Cu2+ ions could destabilise the native fold of PrPC and make the transition to a misfolded state more favourable. Furthermore, Cu2+ induced changes in secondary structure observed for small fragments of the protein are related to the full-length prion protein. An increase in -sheet like character is observed when Cu2+ ions are present, this is due to local Cu2+ ion coordination to the individual binding sites of the amyloidgenic region. Cu2+ induced changes in the secondary structure of the N-terminal domain, PrP(23-126) and full-length PrP(23-231), are attributed to Cu2+ ions binding within the octarepeat region of PrPC. 
Oxidative stress is also a well-recognised feature of Prion diseases. In chapter 4, the effects of Cu2+ catalysed oxidation of PrP on the structure and stability are discussed. 2D 1H-15N HSQC NMR studies of PrPC indicate that specific key residues are perturbed upon methionine (Met) oxidation by H2O2. These residues are involved in the hydrophobic packing of the structured core of the protein, stabilising its ternary structure.  Urea unfolding studies indicate that the oxidation of PrPC by H2O2 and to a greater extent Cu2+ ions with peroxide significantly reduce the thermodynamic stability of PrPC.  Cu2+ catalysed oxidation of PrP causes much more significant alteration of the structure.  2D 1H-15N HSQC NMR spectroscopy indicates that the structured C-terminal portion of PrP becomes a large molten-globule, made of monomeric species.  FT-IR and far-UV-CD spectroscopy indicate that this molten-globule is rich in β-sheet. These observations supports a hypothesis that oxidation of PrP destabilises the native fold of PrPC, making the transition to PrPSc more energetically favourable.  This study gives a structural and thermodynamic explanation for the high levels of oxidised Met residues in scrapie isolates.
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1.01 Protein Misfolding and Amyloid Disease
The western world is suffering from an increase in the aging population, where the sixty plus age group is the fastest growing. This poses a large problem, an increase in age related neurodegenerative diseases. This group of diseases typically results from the accumulation of misfolded proteins in different subsets of neurons, leading to neuronal dysfunction and eventually death (). The relationship between age and misfolding proteins has yet to clarified, there have been a few interesting studies to suggest that with age the body’s ability to degrade proteins decreases  ADDIN EN.CITE (; ). Examples of such diseases include Alzheimer’s disease (AD); Prion disease; Parkinson’s disease (PD); Huntington’s disease (HD).
Prion diseases are perhaps unique compared to other misfolding diseases because of their comparable disease in mammals and the infectious nature of the prion protein. It is believed that natively folded and misfolded proteins are in equilibrium, while in the disease state the equilibrium moves towards the misfolded state (). The aggregated protein often leads to the formation of amyloid fibril plaques. It is generally believed that the toxic specie of disease is the pre-fibrillar oligomeric diffusible form of Aβ  ADDIN EN.CITE (; ). 
Metal ions have been proposed as one of the triggers for a number of misfolding and mis-assembly diseases such as dialysis-related amyloidosis (), PD () and AD (), although it remains to be established if the mechanisms by which metals induce fibrillisation are shared. The metal ion can promote fibrillation, aggregation and misfolding.  Furthermore, Cu2+/+ and Fe3+/2+ ions, have been linked to reactive oxygen species (ROS) generation which may be the source of neurotoxicity and oxidative stress in this group of diseases.
1.02 Transmissible Spongiform Encephalopathies
1.02.1 Prion Disease 
Prion diseases are a group of neurodegenerative diseases that are also referred to as transmissible spongiform encephalopathies (TSEs). These diseases are thought to mostly affect the cortex, thalamus, brain stem, cerebellum of the brain and other neuronal tissue (), and can lead to progressive dementia and may also exhibit some cerebral ataxia (). Examples of such diseases include Scrapie in sheep, Bovine Spongiform Encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker (GSS) disease, Fatal Familial Insomnia (FFI) and Kuru in humans (; ). TSEs are the result of a conformational change in a self-propagating proteinaceous particle, which almost exclusively contains a misfolded form of the prion protein (), the scrapie infectious form, PrPSc. TSEs can either be sporadic, familial or infectious.
Sporadic. This form of the Prion diseases is responsible for the majority of the cases of CJD (; ). Sporadic Prion disease may arise from the presence of a non-inherited mutation in the prion gene, PNRP, or just a spontaneous structural conversion which propagates further misfolding in PrPC (perhaps linked to a yet unidentified set of risk factors). The sporadic form of Prion disease is the most common; it is responsible for about 85% of cases recorded since 1996.
Familial. This form of the disease is a result from an inherited mutation in PNRP, human gene. Forty different mutations have so far been identified to be linked to familial Prion diseases (), Figure 1.01. The first genetic mutation identified was found to be linked to GSS disease and contained a P102L point mutation (). Studies showed that transgenic mice carrying the moPrP(23-231)P101L mutation developed prion amyloid plaques which led to brain dysfunction. Amyloid plaques in the transgenic mice exhibit similar characteristics to those observed in humans with the PrP(23-231)P102L mutation  ADDIN EN.CITE (; ; ). Another common mutation, linked to familial CJD gives rise to additional octarepeat units to be incorporated into the amino acid sequence of PrP  ADDIN EN.CITE (; ). A coupled mutation linked to familial CJD or FFI is found at residue 178, D178N, where the outcome of the mutation is dependent on the polymorphism found at residue 129. This coupled mutation gives rise to familial CJD if residue 129 was found to be a valine (Val) (). On the other hand FFI, a fatal sleeping disorder, is seen in patients with a methionine (Met) residue at position 129 (). There are more of these pathogenic mutations and polymorphous variants which have been identified to be linked to Prion disease, these are summarised in Figure 1.01.





Figure 1.0 1: Mutations and Polymorphic Variants of the Prion Protein




dead relatives (; ; ). Another example is variant CJD, which is due to the consumption of BSE infected beef.
1.02.2 BSE Crisis
The first case of BSE was first recorded in 1986; this later progressed to an epidemic during the 1990’s where almost a million cattle were infected. Cattle between the ages of 2 and 3 years were slaughtered to avoid manifestation of the disease, as the incubation time for BSE is thought to be five years. 160,000 BSE cases in cattle, which led to death, were reported between 1986 and 1997 (). The BSE outbreak was thought to be due to a change in the rendering process of the meat and bone material of dead cattle and sheep (MBM) into the feeding cycle of uninfected cattle, in the late 1970’s (; ). This practice was abolished in 1988, this reduced BSE from ~1,000 cases per week at the height of the crises to ~100 cases a year. According to the world health organisation Britain has seen over 200 cases of variant CJD since 1996, all thought to be due to the transmission of infectious prion material from BSE infected cattle  ADDIN EN.CITE (; ; ). Originally, the expected death toll was predicted to be much higher.
	The polymorphism in PNRP, at codon 129, where either Met or Val is expressed, is linked to the increased susceptibility to develop variant CJD (). Until recently, it was thought that all individuals infected by variant CJD expressed a homozygous Met at residue 129, but a single case has been linked to the heterozygote codon 129 () and this suggests that there may be an imminent second wave of variant CJD cases in the U.K. linked to the consumption of BSE infected beef in the 1990’s ().
As BSE has been linked to variant CJD, through the consumption of infected beef  ADDIN EN.CITE (; ; ), it is important to monitor BSE in cattle, especially those that will enter the human food chain. There are a few post-mortem techniques which allow for the detection of disease, these include conformation-dependent immunoassays, protein misfolding cyclic amplification, capillary gel electrophoresis, flow microbead immunoassay and many more (; ), the main disadvantage of these tests is their requirement of brain homogenates (). Immunoassays still appear to be complicated and not very reliable, when trying to determine the length of time required for incubation before PrPSc can be detected (). Previously, there were no tests which allowed the identification of Prion disease in live animals (). A recent scientific discovery led to the development of a technique which allowed for the detection of PrPSc in the blood, by amplifying PrP samples from the blood to detect infectivity (). The disadvantage to this technique is the 525 hour amplification time. Another technique which uses flow cytometry has also been explored. Again, like the previous technique, this one is time intensive and requires a 20 hour incubation time (). Both of these techniques do not require brain homogenates and are very sensitive but require a long incubation period, making them good techniques but not ideal.
1.02.3 Protein Only Hypothesis
For many years scientists have investigated TSEs and have tried to work out the disease causing agent. The first demonstration of the transmissibility of TSEs was seen in 1937. A common virus vaccine, containing PrPSc infected sheep brain extract, was administered to a population if sheep in Scotland and after two years of administration 10 % of the sheep showed signs of scrapie. Thirty years later, Gajdusek et al. carried out studies on Kuru transmission in monkeys which further proved that there is an infectious route for the propagation of Kuru (). Other studies showed the transmission of CJD () and familial GSS () to animals.
	The transmission of all of these TSEs requires a long incubation period, the period of time between exposure to disease and the onset of disease symptoms. During the 1950’s, this fact led to a study which suggested that the infectious agent was a slow virus (). This hypothesis did not serve a long time in the scientific community and further research indicated the disease agent to be different from viruses, in size and activity. Alternative hypotheses were assumed after the emergence of data which indicated the infectious agent was resistant to nucleic acid degradation () and the minimum molecular weight of the infectious agent to be smaller than any known infectious agent (). One hypothesis stated that the infectious agent could be a small informational molecule, a piece of nucleic acid with a strong protein coat, known as a virino (). As most studies did not identify any links between TSE diseases and a nucleic acid, the hypothesis was replaced by the protein-only hypothesis (). The protein only-hypothesis states that protein, later on dubbed the prion protein by Stanley B. Prusiner, is the material responsible for the transmission and replication of the disease (). Though this controversial hypothesis was first suggested in the late 1960’s it was not until the 1980’s that the hypothesis began to gain acceptance.
Evidence for the protein-only hypothesis is the isolation of the diseased protein from infected brain tissue (). The concentration of the infectious protein was relative to the infectivity (). Also when antibodies and protein destroying agents were used there was a significant reduction in the infectivity of PrPSc, while in contrast nucleases had no effect (). Further evidence came from the study which linked the PrPC to a gene, PNRP. Many familial TSEs have been linked to mutations in PNRP (), these are summarised in Figure 1.01. Other studies, showing mice lacking Pnrp, PrP-null mice, were completely resistant to TSE infections. In addition, evidence supporting the hypothesis came from an in vitro study showing PrPSc acting as a “seed” for the conversion of the normal prion protein (PrPC) (). Seven years later, this study was repeated using a system called protein misfolding cyclic amplification, PMCA, this modified system produced a higher yield of PrPSc (). Also, studies using yeast showed in vitro generation of Sup35, yeast Prion (; ). Fragments, from the N-terminus, of a bacterially produced Sup35 were able to give rise to Prion phenotype in yeast cells upon amyloid fibril formation (; ).  
In 2004, Legname et al. reported the generation of PrPSc, via in vitro misfolding and aggregation of the recombinant form of the protein, led to the infection of mice overexpressing PrP  ADDIN EN.CITE (). Not long after, the successful generation of authentic PrPSc in vitro using PMCA was reported ().  PMCA has proven to be a very useful technique when providing evidence which supports the Prion only hypothesis. This technique was also used to generate infectious PrPSc only using PrPC and PrPSc extracted from the brains of healthy and infected animals, respectively (). Another study uses PMCA for de novo generation of PrPSc in the absence of any brain extract. When this infectious agent was inoculated in wild-type animals, the disease exhibited different characteristics to those previously reported for Prion diseases (). All these studies provide very important information about the infectious agent, but the strongest evidence for the Prion only hypothesis comes from a very recent study. In this study, Wang et al. were able to generate PrPSc, in vitro by PMCA, using only fresh recombinant PrP, RNA and lipids (). 
All of this supporting evidence for the Prion only hypothesis would suggest it’s a widely accepted hypothesis but contrasting evidence suggests otherwise. One particular disproving argument is the presence of Prion strains (). The different TSE strains that arise almost all exhibit different incubation periods, clinical features and neuropathology (), this therefore suggests that different strains will produce different aggregation and misfolded intermediates (; ). However, despite these contradicting studies, this hypothesis is well supported by many groups which show transmission of TSE’s via the Prion mechanism using different organism models, such as yeast. 
1.03 Prion Protein 
1.03.1 The Protein





Figure 1.0 2: A Model of the Native Environment of the Prion Protein




protein is attached to the plasma membrane via a GPI group (). Typically, mammalian PrPC is ~200 amino acids in length and its primary sequence has been shown to be highly conserved in mammals and in some vertebrates. These proteins are non-pathogenic but in some cases undergo a conformational change which gives rise to the pathogenic form of the protein.
1.03.2 Two Isoforms Discovered
There are two existing isoforms of the prion protein; the cellular form which is the non-pathogenic form, PrPC, and the scrapie pathogenic form, PrPSc. Both isoforms share the same primary sequence but differ in their secondary structural conformation. The pathogenic isoform was defined as a proteinaceous infectious particle lacking nucleic acid and denoted prion (). Both protein isoforms are membrane proteins, but PrPSc are resistant to the digestion of proteinase K. However, the proteinase will remove 67 residues from the N-terminus to produce a shorter yet more hydrophobic and protease resistant fragment, PrP 27-30, so called due to its glycosylated molecular weight of 27-30 kDa. This is a ~160 amino acid residues fragment with two glycosylated residues at positions 181 and 197. The non-pathogenic form, PrPC, is readily broken down in the presence of the enzyme  ADDIN EN.CITE (; ; ). Not all PrPSc strains are resistant to proteinase K, albeit the resistance of PrPSc to enzyme digestion has been beneficial for isolating the different isoforms of the prion protein,  ADDIN EN.CITE (; ; ; ; ). When extracted, PrPC was found to be soluble whereas PrPSc, had polymerised into amyloid rods (). The main characteristic used to distinguish between the two isoforms is the difference in their secondary structures, this is summarised in Figure 1.03.  The model of PrPSc shown in Figure 1.03b is based on chocolate 

Figure 1.0 3:  Structures of PrPC and PrPSc
The structural differences between the two isoforms, PrPC and PrPSc are highlighted here. a) NMR resolved PrPC structure () residues 121-230 are shown, N-terminal natively unfolded, residues 23-126. b) A theoretical structural model of PrPSc (). c) A schematic diagram showing features within sequence and secondary structure of PrPC.

electron crystallography studies of two dimensional crystals of the infectious particle. 
Structure of PrPC. The C-terminal domain between residues 126-231 is mainly α-helical (), as shown in Figure 1.03a. The C-terminus is made up of three α-helices; spanning residues 144-154, 173-194, and residues 200-228 (in mice). PrPC also has two β-strands at positions 128-131 and 161-164 which form an antiparallel β-pleat sheet, this is summarised in Figure 1.03c. The two cysteine (Cys) residues, found at positions 179 and 214, form a disulphide bridge. The N-terminal domain between residues 23-126 is unstructured and exhibits a high degree of main-chain flexibility (). The N-terminal domain is made up of two regions; the octarepeat and the amyloidogenic. The octarepeat region is residues 58 to 91 in humans; this region consists of a repeating eight amino acid residue sequence, PHGGGWGQ. It has been found that the removal of the octarepeat region from the full length prion protein slows down the progression of prion diseases (). The so called amyloidogenic region, due to its ability to generate amyloids, spans residues 90 to126 and has been shown to be essential for the infectivity of the disease and amyloid formation.
A number of different mammalian prion proteins have had their three dimensional structure determined using NMR  ADDIN EN.CITE (; ; ; ; ; ; ). The NMR structure produced by Zahn et al. is presented in Figure 1.03a. The secondary structure of the C-terminus of human PrPC is very similar to those obtained from other mammals, this is understandable as the primary sequence is highly conserved between mammals (; ). The prion proteins from chicken, turtle and frog also share a similar structure ().  
	Structure of PrPSc. Atomic level determination of PrPSc structure is problematic using X-ray crystallography and Nuclear Magnetic Resonance (NMR) studies due to its insolubility. In 2002, Wille et al. led the investigation into the structure of the diseased form of the protein, using electron crystallography to analyse the two dimensional crystals formed by PrP27-30, the product of proteinase K digestion of PrPSc previously described (). In some cases, the two dimensional crystals resulted in the formation of prion rods, suggesting that both are alternative polymerisation products, therefore, are infectious (). Fourier Transform Infrared spectroscopy (FT-IR) has shown that there is an increase in  β-sheet character when comparing the structure of PrPSc to PrPC, yet at the same time 30-40 residues are still found in their native α-helical conformation (). Studies using antibodies specific to the C-terminus of PrPC have been shown to also acknowledge the presence of PrPSc (), the difference in structure of PrPC and PrPSc is highlighted in Figure 1.03. There have been speculations about what happens to the disulphide bridge during the conformational change, it is thought that the bridge remains intact, therefore, it is not involved in intramolecular β-sheet formation (). This leads to the possibility that α-helix II and III are both unchanged in the conversion of PrPC to PrPSc, thus, giving a PrPSc with a structure rich in β-sheet between residues 90-165 and α-helical rich region between residues 170-228. The theoretical three dimensional structure of PrPSc is presented in Figure 1.03b. Another study using recombinant PrP to generate fibril preparations, suggested a hydrogen bonded (H-bonded) cross-β structure to define the amyloid core of the protein (; ). There remains a possibility that these structures generated in vitro are different to those from the in vivo scrapie isolates. 
	Infectivity refers to the ability of a disease agent to enter, survive and multiply in a susceptible host (). Unlike other neurodegenerative diseases, TSE’s are special in that they have the ability to transmit horizontally from one host to another, however, not through a parent to child relationship, and overcoming the species barrier in some cases. One prime example of this is the transmission of the infectious Prion agent from BSE infected cattle to healthy humans. This leads to the development of CJD and finally to death in humans. This can also be seen within the same species, an example of this is Kuru, a Prion disease that spread though human to human transmission. 
Unlike Alzheimer’s disease, where the disease agent has been identified to be a soluble oligomer rather than the large amyloid fibrils, the infectious agent for Prion diseases has been linked to many aggregate states (). There is much dispute in current literature about the size of the smallest infectious unit; some groups suggest PrPSc monomer isolates to be responsible for infection  ADDIN EN.CITE (; ; ), though this is yet to be confirmed (; ). While, other groups use radiation inactivation  ADDIN EN.CITE (; ; ) and studies involving the solubilsation of liposomes () to confirm the minimal infectious unit to be made of 2 to 6 PrP molecules, resulting in a 50 to 150 kDa sized oligomer. However, there are no reports which show the isolation of such toxic and small oligomers. Toxicity refers to the ability to be toxic and cause death (). TSE’s are not only transmissible but are also toxic. A recent study by Silveira et al. compared the infectivity of different oligomeric states of PrP (), in doing so the group found out that the infectivity was markedly higher in oligomers, 300-600 kDa in size, when compared to fibrils. The same study also showed that any oligomer smaller than a pentamer presented no activity. Although, direct monitoring of toxicity was not investigated in this study, it does suggest that oligomers of 14 to 28 PrP molecules in length show more infectivity than fibrils, therefore, oligomers may be responsible for the initiation of TSEs.
1.03.3 Copper Coordination Geometry to PrPC
The N-terminal domain (residues 23 to 126) of PrP is highly disordered  ADDIN EN.CITE (; ) and has the ability to bind Cu2+ ions in vivo (), there are as many as six Cu2+ ion binding sites within the N-terminal unstructured domain of PrPC (). Within the mammalian form PrPC, there is a repeating motif of eight amino acids, typically four octarepeats between residues 58 to 91, with each repeat containing a histidine (His) residue.  This highly conserved region binds four Cu2+ ions with identical coordination geometry  ADDIN EN.CITE (; ), shown in Figure 1.05c. A crystal structure of the Cu2+ bound octarepeat motif (residues HGGGW) indicates a square-pyramidal geometry (), demonstrated in Figure 1.04d, involving coordinating nitrogen and oxygen ligands from the main-chain as well as the imidazole side chain. It has also been shown that at sub-stoichiometric levels, Cu2+ ions will bind with a higher affinity to the octarepeats via multiple His residues  ADDIN EN.CITE (; ; ), Figure 1.04b.
	Cu2+ ions binding outside the octarepeat region, are centred at His95 and His110 in the mouse sequence (His96 and His111 in the human sequence), in the amyloidogenic region between residues 90 to 126  ADDIN EN.CITE (; ; ; ; ; ; ; ; ; ). A square-planar/tetragonal complex is formed upon chocolatespuppies m


Figure 1.0 4: Cu2+ Coordination to the Octarepeats Region
a) PrP sequence, residue 58 to 126, highlighting the two Cu2+ ion binding regions, Cu2+ binding sites highlighted in blue. b) Multiple His residues from the octarepeats region binding to a single Cu2+ ion. c) Multiple Cu2+ ions binding to each His side-chain. d) Schematic based on the crystal structure of Cu2+ bound to HGGGW by Burns et al. (). e)  Schematic representation, adapted from Jones et al., showing the binding of Ni2+ or Cu2+ ions, represented by X, to either of the two binding sites in the amyloidogenic region, PrP(90-126) (). 


Cu2+ binding, which involves the His imidazole nitrogen N and the main-chain amides that precede the His  ADDIN EN.CITE (; ), Figure 1.04e. It is notable that amide coordination precedes the His residue, Ni2+ ions are also able to bind in a similar coordination geometry. In the octarepeats, proline (Pro) precedes the His residue, therefore, amide coordination is only possible following the His residue, Figure 1.04b-c.
1.03.4 Copper Affinity 







Figure 1.0 5: PrPC with Cu2+ Affinities





(). In these instances, Cu2+-chelating proteins such as metallothionine-III and serum albumin become saturated. This is when the presynaptic membrane localised PrPC (), with its affinity for Cu2+ ions and large number of binding sites, may bind these remaining free extracellular ions. 
1.04 Mechanism of Misfolding and Aggregation
The propagation of Prion disease is thought to involve PrPSc assuming a template role to aid the conversion of PrPC, summarised in Figure 1.06a. There are many studies which support this theory; one particular study uses transgenic mice expressing mouse PrP, MoPrPC, and Syrian hamster PrP, SHaPrPC (). When these mice were injected with MoPrPSc, the infectious particles facilitated the conversion of MoPrPC to MoPrPSc, the same was observed when the transgenic mice were inoculated with SHaPrPSc. Thus, indicating only the PrPC with the corresponding sequence to the PrPSc present, undergo conformational changes. PrPC is assumed to enter a state of partial unfolding before it is induced to misfold into PrPSc (). This partially unfolded intermediate is referred to as PrP*. Some in vitro studies have tried to simulate this intermediate by using 2 M guanidinium chloride or sonication  ADDIN EN.CITE (; ; ). There is some debate about the involvement of other cofactors which may facilitate the conversion of PrPC to PrPSc; these are commonly referred to as protein X. Hypothetically speaking, the presence of protein X would cut down incubation time, while the absence of  this  protein  may  prolong  propagation  of   the  disease  (). Research led to the identification of many genes that are responsible for protein X, but transgenic knockouts of these genes failed to yield any difference in the incubation time ().
	There are many studies to suggest the involvement of non-PrP particles in the facilitation of PrPC conversion to PrPSc and the progression of the disease (; ). These cofactors include a neuronal cell adhesion molecule (N-CAM) () and a receptor for Laminin, 37 or 67 kDa in size (). More recently, cofactors that have been shown to mediate misfolding in cell cultures have been identified, such as lipoprotein receptor 1 () and glypican-1 (). More recently, Graham et al. have shown specific connections between scrapie-associated fibrils (SAF), isolated from mouse brains, and sodium/potassium transporting ATPase (). It seems that PrPSc misfolding, in vivo, is aided by the sodium/potassium transporting ATPase, this transport protein is not strain specific.   PrPC has also been shown to bind Cu2+ ions, nucleic acids (), and lipids (). These studies on PrP cofactors are very important in elucidating the function protein and also the propagation of the disease.











Figure 1.0 6: Two Methods of PrPSc Propagation






The protein is expressed in the form of a single protein chain consisting of 254 amino acid residues. Once the 254 amino acid residue peptide is formed it is then translocated to the endoplasmic reticulum, this is because it contains an N-terminus signal peptide. Each compartment of the cell cycle is susceptible to the conversion process of PrPC to PrPSc, therefore, it is very important to understand this process. Some studies have indicated the production of small amounts of incorrectly folded PrP at this stage, these are then degraded using proteasome in the cytosol (; ). Once the protein is in the endoplasmic reticulum lumen it undergoes post-translational modifications, these include the cleavage of the first 22 amino acids from the N-terminus, corresponding to the signal peptide, and the last 23 amino acids from the C-terminus, revealing a serine (Ser) residue at position 231 which allows for the attachment of a GPI anchor. Further modifications include the formation of a disulphide bridge between two cysteine residues at positions 179 and 214 and the glycosylation of asparagine residues at position 181 and 197, which may influence its stability and fibrillisation (all residues given here are specific to the human sequence). The mature PrPC, now 209 amino acid residues in length (residue 23 to 231), passes by the golgi apparatus on route to the cell surface. The cellular trafficking pathway is summarised in Figure 1.07.





Figure 1.0 7: Cell Trafficking of PrP




have been shown to enhance endocytosis in the neurons (; ), while a minority undergoes extracellular secretion  ADDIN EN.CITE (; ; ).
PrPC endocytosis is impaired in the absence of the N-terminus, therefore, indicating the importance of amino-terminal in the recycling of this potentially harmful protein  ADDIN EN.CITE (; ; ). There is much debate about the process of PrPC internalisation; some studies have shown endocytosis via lipid rafts or caveolae  ADDIN EN.CITE (; ; ; ), while, other studies show internalisation through clathrin coated pits  ADDIN EN.CITE (; ; ). Once internalised, research has shown that PrPC has one of two fates; the first of which is being recycled back up to the cell surface, the other involves the degradation of the protein in the lysosome  ADDIN EN.CITE (; ; ). The conversion to PrPSc and the formation of oligomers and fibres is thought to take place at the plasma membrane surface and also in endosomes and lysosomes within the cell, refer to Figure 1.07. The composition of the membrane may influence PrP misfolding (; ).
1.06 Normal Function of PrPC
The actual function of PrPC is still unclear, although, there are indications of these proteins having a role as an anti-oxidant (). Other research has shown the involvement of PrPC in signal transduction, while others have demonstrated PrPC to have a role in the nervous system and the immune system. Here, I discuss some of the possible functions that are carried out by PrPC. 
	The Nervous System. Initial research tried to relate PrPC to the nervous system, by making PrP-null transgenic mice, called Zurich I, by replacing codon 4-187 with a neomycin phosphotransferase (neo) expression cassette. These mice showed no behavioural or learning defects (). A similar study using transgenic mice, called Edinburgh made by an interruption at codon 93, gave results similar to those seen for the Zurich I transgenic mice (). Taken together both of these studies, they suggested either PrPC is not essential for normal development or that there is a compensatory effect by a redundant protein. However, contradictory results were obtained by PrP-null transgenic mice, where Pnrp has been completely removed. These mice experienced normal development but at advanced ages developed sever ataxia and prukinje cell degeneration  ADDIN EN.CITE (; ; ). The reason for the contradiction in phenotypes is that the latter experiments involved the removal of a large part of the open reading frame (ORF) (), also the ataxia observed was seen to be caused by the over expression of the Doppel protein (Dpl) (). Reintroduction of PrPC rescued these mice expressing neurodegenration  ADDIN EN.CITE (; ), suggesting a role for PrPC in the nervous system, therefore the presence of PrPC is thought to control the neurotoxicity of Dpl ().
	Other studies involving transgenic mice, Zurich I, showed that in the absence of PrPC these mice developed functional changes in their glutamatergic system, but their dopaminergic and adenosinergic systems were unaffected (). While other studies show a link between the decrease in anxiety to PrP-null mice, thus, suggesting that these mice are unable to adapt to high levels of stress (). Zurich I mice have also demonstrated abnormalities in their  circadian rhythms and sleeping patterns, when PrPC was overexpressed the transgenic mice developed wild type phenotypes (; ). This raises the possibility that Prion diseases which result in the development of abnormal sleep-wakefulness patterns, such as fatal familial insomnia (FFI), are maybe linked to the loss of PrPC expression and function (). 
	PrPC plays a role in memory and cognition as observed in humans, further proving the importance of this protein in the nervous system. The polymorphism at codon 129 is associated with many disease characteristics; when there is at least one Val allele a decrease in cognitive performance in the elderly is noted (; ), early onset of cognitive dysfunction () and the rapid decay of intellectual abilities in Downs Syndrome patients (), when compared to patients with homozygous Met at residue 129  ADDIN EN.CITE (; ). Dutch () and Polish () patients expressing a homozygous polymorphism at codon 129, in particular 129VV, have a higher risk for developing AD than heterozygous carriers. However, German patients expressing the 129MM polymorphism showed a higher susceptibility to AD (). All of these studies on knockout mice and Prion disease patients show that PrPC plays an important role in the nervous system.   
	The Immune System. Previous studies on PrPC have failed to show an appreciable function in the immune system and the reason for the expression of this protein in the hematopoietic progenitors and mitotic lymphocytes is due to the rapid turnover rate in the cell membrane (). Recently, it has been viewed that the expression of PrPC is not homogenous, this is true across species and immune cells, when granulocytes are undergoing maturation the expression of PrPC is down regulated, while, the opposite is seen when myeloid antigen-presenting cells are maturating (). When looking at human and sheep lymphoid cells the up-regulation of PrPC was observed upon maturation yet in mice the opposite effect is noted  ADDIN EN.CITE (; ). Although, more research needs to be done on PrPC in immune cells, the progress that has been made suggests an important role for PrPC in the immune system.
	Cell Signalling. Early studies suggested that PrPC mediated cell signalling by activating Fyn non-receptor tyrosine kinase (). GPI-linked PrPC is extracellular while Fyn kinase is found intracellularly, therefore, suggesting this process is not direct. One study has shown that PrPC interacts with and stabilises the transmembrane neuronal cell adhesion molecule, N-CAM, this then leads to the phosphorylation of Fyn and allows for the N-CAM-mediated neurite growth ().  This does not suggest that PrPC-mediated signal transduction has to only go through this path; there are other intermediate proteins which act as the intermediate in signal transduction such as clathrin and caveolin-a.
	Role of Cu2+ Ions. PrPC is concentrated at presynaptic membranes, where Cu2+ ions are also highly localised ().  Recent studies show that the prion protein has a high degree of structural homology with the ZIP family of zinc ion transporters () and altered PrP expression perturbs Cu2+ metabolism ().  Furthermore, Cu2+ and Zn2+ ions promote the endocytosis of the PrPC at physiological levels (; ).  Unlike, the principle copper ion transport protein, CTR1, PrPC does not require the reduction of Cu2+ ions to allow intracellular transport. However, knockout cell-lines indicate PrPC is not the principle mechanism by which Cu2+/Cu+ ions are transported into the cell  ADDIN EN.CITE (; ). 
PrPC as an Anti-Oxidant. The reduction-oxidation (redox) properties of Cu2+ ions can cause the cleavage of PrPC main-chain  ADDIN EN.CITE (). Prion protein knockout mice are sensitive to Cu2+-induced oxidative stress  ADDIN EN.CITE (), which supports the suggestion that PrPC can have an anti-oxidant activity, sacrificially quenching hydroxyl radicals, associated with Cu2+ redox cycling  ADDIN EN.CITE (; ). It is believed that proteins with solvent accessible Met residues can serve as a first defence against oxidative damage, scavenging reactive oxygen species (ROS) before they react with other cellular components ().  It has been suggested that a function of PrPC might be to act as a sacrificial quencher of ROS generated by Cu2+ catalysed oxidation (). The antioxidant role of PrPC is highlighted by the increased oxidative stress observed in PrPC knock-out mice  ADDIN EN.CITE (; ). A study by Ikeda et al. relates PrPC to a role in anti-oxidative stress and the progression of liver fibrosis ().
The Rest of the Body. As most studies are usually directed at nervous system dysfunction, the emphasis on the rest of the body has been limited. However, PrP-null mice were used to ascertain a difference in the muscle activity compared to wild type mice, depletion in the locomotor activity was observed (). This study along with others reported no change in mitochondrial respiration (; ). Nico et al. proved that these results are an indication of modifications in anxiety level or motor coordination rather than a direct measure of muscle function (). Based on these findings PrPC is assumed to be related to stress response in neuromuscular disorders (). 
The involvement of PrPC in the liver function has also been suggested. One study showed that if the expression of PrPC was upregulated for long periods of time in frogs the secretion of proopiomelanocrotin (POMC) was reduced (). As POMC has a crucial role in the melanocrotin system, in regulating weight homeostasis and feeding behaviour (), it is important to improve our knowledge about the relationship between the function of PrPC and the pituitary gland.
1.07 Copper and Prion Disease
The ability of Cu2+ ions to bind to PrPC in vivo has ramifications for Prion diseases, recently reviewed  ADDIN EN.CITE (; ; ). Furthermore, Cu2+ ions have an influence on the structure and stability of PrPC fold which may influence misfolding and eventually leads to disease; this is further discussed in chapter 3. It has been shown that metal imbalance is a feature of Prion disease () and when isolated from diseased brain, PrPSc has been found to be occupied with Cu2+ ions (). Cu2+ binding induces protease resistance in PrP  ADDIN EN.CITE (; ) and the presence, or absence, of Cu2+ ions may also confer different strains of Prion disease  ADDIN EN.CITE (; ). It is the Cu2+ binding to both regions in the N-terminal domain, the amyloidogenic and octarepeat regions, of PrPC that has been linked to Prion disease  ADDIN EN.CITE (; ; ). The natively unstructured amyloidgenic region, centred between the octarepeats and the structured C-terminal domain, has been shown to be essential for prion propagation and binds Cu2+ ions with a high affinity.
A mutation at codon 53, which involves the insertion of 144 base pairs (bp) leading to the presence of six additional octarepeats has been reported for some individuals in a southern English family (). Owen et al. showed that there are two to nine additional octarepeats found in CJD suffers. However, the same study proved that the deletion of one of the four octarepeats or the addition of an extra (PHGGGWGQ) repeat did not lead to disease (). More recently, the PrP mutant which gives rise to the nine additional octarepeats has been shown to have the inability to undergo Cu2+-mediated endocytosis () and so in human Prion disease, metal binding to PrP is altered. In another study, the total elimination of the octarepeats was shown to delay disease progression ().

Oxidative stress is an imbalance in the equilibrium of the pro-oxidant/free radical production and the antioxidant defences. Many neurodegenerative diseases have been linked to acute and chronic forms of oxidative stress. Prion diseases are characterised by oxidative stress  ADDIN EN.CITE (; ).  For example, levels of oxidative stress markers, are reported as being significantly increased in the brains of PrPSc-infected mice  ADDIN EN.CITE (; ) and in the brains of patients suffering from CJD  ADDIN EN.CITE (; ).  In addition disease infected cells and animals are more sensitive to oxidative stress  ADDIN EN.CITE (; ; ; ; ).
Daily, the human brain produces >1011 free radicals (), in cases where there is build-up of pro-oxidant species the reactive oxygen species (ROS) are generated. In the electron transport chain, the stepwise addition of electrons (e-) observed during the reduction of molecular oxygen to water induces the generation of ROS species. The major sources of ROS in vivo are the Harber-Weiss and the Fenton reactions, associated with Fe3+/2+ and Cu2+/+ ions (), see below. 
O2- + H2O2  OH- + •OH + O2 (Harber-Weiss reaction)
Mn+ + H2O2  OH‑ + •OH + M(n+1)+ (Fenton reaction) 
The generated ROS products include hydroperoxyl radical (HO•2), superoxide radical (•O2-), hydrogen peroxide (H2O2), and the hydroxyl radical (•OH).
The prion protein binds Cu2+ ions in their redox active form (), in the presence of a reductant will lead to oxidation. Thus, physiological amounts of reductant (e.g. ascorbate) will readily generate ROS. The generation of the ROS product H2O2 will cause Met residues within PrPC to be oxidised. Studies have shown that a high proportion of PrPSc contains Met residues which were oxidised to their sulfoxide form (). This is discussed in further detail in chapter 4.

A relatively recent report in Nature (2009) has shown a direct interaction between amyloid-β (Aβ) oligomers and PrPC (). The study showed that PrPC mediates the pathological actions of Aβ oligomers at the neuronal synapses (). Significantly, studies showed transgenic PrP knockout mice were immune to Alzheimer’s disease (AD) like pathology. This is a key finding indicating PrPC can mediate the impairment of synaptic plasticity caused by toxic Aβ oligomers. This represents a major new avenue in understanding AD and also raises the possibility that AD and TSE’s share a common down-stream mechanism of action. In particular PrPSc oligomers may bind to PrPC in the same region as oligomeric Aβ (). In chapter 5 the interactions of Aβ40 and Aβ42 with PrP are explored, in particular the influence of PrP on the kinetics of Aβ fibril formation is studied. For a more detailed account on the interaction please refer to Chapter 5.
 
Here, I have used a range of spectroscopic and biophysical techniques to investigate the influence of Cu2+ ions on the structure, and stability of PrPC. Below; I have listed the main aims of each result chapter:
1)	With ramifications for Cu2+ ions promoting misfolding, in chapter 3 the effects of Cu2+ ions on the folding stability of PrPC are investigated 
2)	With surprisingly little understanding about the global influence of Cu2+ ions on PrPC structure, also in chapter 3, I monitor secondary structure changes observed upon coordination of Cu2+ ions to the full length prion protein and relate them to the changes observed in the smaller fragments of PrP. 
3)	In chapter 4, using 2D 1H-15N NMR, Fourier Transform Infrared (FT-IR) and Ultraviolet Circular Dichroism (UV-CD) I aim to investigate how the structure and stability of PrPC are perturbed by Cu2+ ion catalysed and H2O2 oxidation. 



























The following is a brief explanation of the fundamental theory behind some of the biophysical techniques used in this thesis.
2.01.1 Absorbance (UV-Vis) Spectroscopy
For further information on absorbance spectroscopy I can suggest chapter 13 by Alex Drake in “Methods in Molecular Biology” volume 22 (). This technique uses the ultraviolet (UV), 180 to 400 nm, and visible (Vis) spectrum, 400 to 800 nm. It is a particularly useful approach to determine the concentration of proteins. Side-chains belonging to tryptophan (Trp), tyrosine (Tyr), phenylalanine (Phe) and a disulphide bond act as concentration monitors of proteins at 280 nm. Using the Beer-Lambert law (eq 1) which highlights the relationship between absorbance and concentration of a protein:
									(eq 1)
Rearrangement of this equation to make concentration the product is demonstrated by eq 2:
									(eq 2)
where A is the absorbance, c is the molar concentration of a protein, ε is the extinction coefficient of the side-chains and l is the path-length in centimetres (cm). At a wavelength of 280 nm the absorbance contribution from the Phe residue is very small, thus, not considered. Therefore, to work out the concentration of a protein in a 1 cm path-length cuvette using the absorbance at 280 nm you would use the following equation (eq 3):
					(eq 3)
where εx is the extinction coefficient and Nx is the number of residues (). It is inaccurate to determine concentration from absorbance values above 3.0 as less than 0.1 % of the light transmitted is being detected; therefore, only measurements between 0.1-1.0 absorbance are used, although, the theoretical optimal absorbance is 0.864. Quartz cuvettes are used because, unlike glass, quartz does not absorb light in the UV- or the Vis-regions. 
2.01.2 Gel Filtration Chromatography
This is a brief description of gel filtration chromatography for more information on this method please refer to chapters 5 and 9 in “Protein Structure: A practical Approach” (; ). Gel filtration chromatography may also be referred to as size exclusion chromatography (SEC) or gel permeation chromatography. This method allows for protein separation according to their size, using a cross-linked gel medium for separation, made from poriferous beads. As the separation medium is made up of beads there is always space for the larger proteins to move through while the smaller protein molecules are retained in the free space in the beads. This process allows for the larger proteins to be eluted first, therefore, with a lower elution volume than that of smaller proteins, highlighted in Figure 2.01. 








Figure 2.0 1: Gel Filtration Chromatography






For a review on fluorescence spectroscopy refer to: chapter 15 by Paul G. Varley in “Methods in Molecular Biology” volume 22 () and to “Principles of Fluorescence Spectroscopy” by Joseph R. Lakowicz (). When substances are exposed to light they are excited from the ground state to a higher energy level. As molecules return back to their ground state they emit energy in the form of heat or in some cases in the form of light radiation, the radiation is referred to as fluorescence.  This process is summarised in Figure 2.02a. Each electronic energy state has different vibrational energy levels. When a substance exhibits conjugated double bonds, these contain delocalised electrons, it can fluoresce. Intrinsic or naturally occurring fluorophores include tryptophan (Trp), tyrosine (Tyr), some cofactors and some DNA bases. The second group of fluorophores is referred to as extrinsic and includes chemicals such as protein labels which include thioflavin T (ThT), membrane probes and DNA-binding probes. Due to the sensitivity of fluorophores only small amounts of substances are required to measure changes in fluorescence, this is the advantage of using fluorescence spectroscopy.
Multi-well Fluorescence. Light, generally from a xenon lamp, passes through a monochromator (a light filter) this allows for the selection of particular excitation wavelength. The fluorescence is passed through a monochromator before detection. The product is then detected perpendicular to the excitation light. This is summerised in Figure 2.02b. Refer to section 2.3.11 for information on the experimental techniques.




Figure 2.0 2: Fluorescence Spectroscopy
This is a schematic highlighting the key features of: a) the fluorescence process adapted from P. G. Varley () and b) the steps involved in obtaining a spectrum of a substance using multi-well fluorescence taken from C. J. Sarell () (originally adapted from J. R. Lakowicz ()).

485 nm upon excitation a wavelength of 455 nm (). Salts such as NaCl have no effect on ThT binding ().
2.01.4 Circular Dichroism (CD) Spectroscopy
For reviews on circular dichroism (CD) I can recommend; chapter 16 by Alex F. Drake in Methods in Molecular Biology volume 22 () and chapter 10 by Stephen R. Martin et al. in Biophysical Tools for Biologists, Volume 1: In Vitro Techniques (). This technique measures the difference in the absorption of right (AR) and left circular polarised light (AL). Therefore, for a sample to be CD active it must be chiral. Amino acids are optically active as they contain α-carbons with four different groups attached. The chiral character of a sample allows for the differential absorption of the L- and R- circularly polarised light (ΔA), this will produce a CD spectrum. The difference in absorption can be related to the molar extinction coefficient using the Beer-Lambert’s law (eq 4):
						(eq 4)
where Δε is the difference in molar extinction coefficient, ΔA is the difference in absorbance (AL - AR), c is the molar concentration and l is the path-length of the sample in centimetres. 
	The relationship between the direct CD measurements (in millidegrees), θ, and Δε, M-1cm-1, is highlighted below in equation 5 (eq 5). Please note that the relationship between CD measurement and change in absorbance is θ = ΔA . 33,000.
								(eq 5)
where θ is the direct CD measurement in millidegrees, c is the molar concentration and l is the path-length of the cuvette in centimetres.
	Secondary Structure. The far-UV region spans wavelengths 170 to 250 nm, this region is essential for measuring secondary structural changes of a protein. Far-UV-CD uses the two electronic absorptions of the backbone amide group, the electronic dipole from the π – π* transition at 190 nm and the magnetic dipole from the weaker n - π* transition at 210 nm. These transitions dominate the CD spectrum to produce a trace characteristic of the ψ (psi) and φ (phi) torsion angles, therefore, are characteristic of secondary structure of the polypeptide chain. Different structural conformation produce characteristic CD spectrum, summarised in Figure 2.03. Due to the versatile nature of far-UV-CD it has been used throughout this thesis to measure changes in secondary structure under different conditions; pH, temperatures, pressure and binding to metal ions. Also, it is a valuable technique for chemical and thermal denaturation studies.
Visible Region. This region of the CD spectrum is useful for monitoring metal – ligand binding and it makes use of the wavelengths from 300 to 800 nm. The visible region monitors the difference in the charge transfer, metal, d – d, and ligand, p – p*, transitions. As with far-UV-CD, a trace is only observable if a metal is bound to a ligand in a chiral environment. Therefore, free metal ions, even with d – d transitions, are CD silent. There are three particular effects which contribute to the activity of a metal – ligand complex, these are:






Figure 2.0 3: Far-UV Circular Dichroism Spectra
This far-UV-CD illustration demonstrates the different structural conformations (such as α-helix, β-sheet, polyproline II and irregular structure) and the characteristic traces that are produced. This figure has been adapted from S. Brahms et al. ().


2)	Conformational effect arises from different complexes of the ligand to the transition metal which leads to ring puckering (). 
3)	Vicinal effect which results from substitutions in the amino acid side-chains ().
The Cu2+ and Ni2+ ion coordination to the backbone amide will result in a strong visible effect  ADDIN EN.CITE (; ).
2.01.5 Fourier Transform Infrared (FT-IR) Spectroscopy
For a review refer to chapter 14 by Pravez I. Haris et al. in Methods in Molecular Biology volume 22. Fourier Transform Infrared (FT-IR) spectroscopy makes use of the nine infrared active amide vibrations belonging to amide bonds in proteins and polypeptides (; ). The most useful, for secondary structural information, is the amide I absorption band, which absorbs between 1690 to 1600 cm-1. This band arises from the bending vibrations of the N-H bonds and stretching vibrations which comes C-N bonds coupled to the stretching vibrations of C=O (; ). 
The hydrogen bonding, involving C=O and N-H groups, is dependent on the secondary structure of a protein. This is useful when determining secondary structure using this technique as the amide I band depends on the nature of the hydrogen bonding. As globular proteins often contain more than one type of secondary structural folding, this leads to the presence of more than one amide I maxima. Early use of this technique may have been limited low resolution amide I band due to the overlap of different maxima, however, deconvolution procedures have allowed for the separation of the overlapping maxima, therefore, making it easy to estimate the folding of the protein  ADDIN EN.CITE (; ; ; ). Once deconvoluted each area of the amide I band represents a certain secondary structure fold: 1640-1620 cm-1  ADDIN EN.CITE (; ; ; ; ; ) and 1695-1670 cm-1 both are normally associated with β-sheet structure, β-turn also produces the same maxima. The 310-helix structure has been shown to absorb at 1665 cm-1 (for simplicity reasons this is not included in Figure 2.04a)  ADDIN EN.CITE (; ; ). The absorption range between 1648 and 1657 cm-1 is usually attributed to α-helical structures. The absorption wavelength of irregular structures may sometimes overlap with α-helix structures, however, it is usually associated with a lower frequency of 1644 cm-1  ADDIN EN.CITE (; ; ; ; ; ). For a simplified overview of the different regions of the amide I band refer to Figure 2.04a.





Figure 2.0 4: FT-IR Spectra




2.02.1 Chemicals and Suppliers
I have listed the chemicals that were used throughout this thesis in the table below, stating their supplier, molecular weight and their purity.
Table 2.0 1: Chemicals used Throughout the Thesis
Chemicals	Supplier	Molecular Weight	Purity/ Grade
Hydrochloric Acid (HCl)	BDH Biochemical	36.46 g/mol	Spectroscopy grade 1.18
2-(N-morpholino)ethanesulfonic acid (MES)	BDH Biochemical	213.25 g/mol	99 %
Sodium Acetate (NaOAc)	BDH Biochemical	82.03 g/mol	≥ 99 %
Sodium Hydroxide (NaOH)	BDH Biochemical	40.00 g/mol	≥ 99 %
Deuterated Water (D2O)	Cambridge Isotope Laboratories, Inc.		99.9 %
Catalase (from bovine liver)	Sigma - Aldrich	(1,824 units/mg)	
Copper Chloride (CuCl2)	Sigma - Aldrich	170.48 g/mol	≥ 99.99 %
Ethylenediaminetetraacetic acid (EDTA)	Sigma - Aldrich	292.24 g/mol	≥ 99.995 %
N-ethylmorpholine (EM)	Sigma - Aldrich	115.20 g/mol	~ 99 %
Guanidinium Chloride (GdmCl)	Sigma - Aldrich	95.53 g/mol	
2-[4-(hydroxyethyl)piperazin-1-yl] ethanesulfonic Acid (HEPES)	Sigma - Aldrich	238.30 g/mol	≥ 99.5 %
Hydrogen Peroxide (H2O2)	Sigma - Aldrich	34.01 g/mol	30 % (w/w)
3-(N-morpholino)propanesulfonic Acid (MOPS)	Sigma - Aldrich	209.30 g/mol	≥ 99.5 %
Phosphate Buffer (PB)	Sigma - Aldrich	174.30 g/mol	
Sodium Chloride (NaCl)	Sigma - Aldrich	58.44 g/mol	≥ 98 %
Thioflavin T (ThT)	Sigma - Aldrich	318.87 g/mol	
Urea	Sigma - Aldrich	60.06 g/mol	≥ 99.5 %
	
The following is a list of the cuvettes, NMR tubes, Fluorescence plates and gel filtration chromatography columns used in this thesis and their specifications. 
Table 2.0 2: Consumables used Throughout the Thesis
Consumables	Supplier	Specifications 
1 cm Path-length Cuvette	Hellma	1 mL volume, made from Quartz Suprasil
1 cm Path-length Cuvette	Hellma	3 mL volume, made from Quartz Suprasil
0.1 cm Path-length Cuvette	Hellma	0.3 mL volume, made from Quartz Suprasil
NMR Tube	Wilmad Lab Glass	5 mm medium wall, 7” length, 300 MHz 
NMR Tube	Shigemi	BMS-003 shigemi tube
Gel Filtration Chromatography Column	GE Healthcare 	Superdex 75 10/300 GL column
Gel Filtration Chromatography Column	GE Healthcare	Superdex 200 10/300 GL column
96 Well Plate (Clear)	Falcon	350 µL capacity per well, clear colour

2.02.2 Synthetic Protein and Fragments
F-moc chemistry was used to synthesise various fragments of PrP, which were N-terminally acetylated and C-terminally blocked in order to mimic regions of PrP within the full-length protein. The peptides were removed from the resin and de-protected before purification by reverse-phase HPLC. The samples were characterised using mass spectrometry and 1H NMR spectroscopy. The proteins made using this process are Aβ40 and Aβ42 and PrP fragments including; the octarepeats, PrP(58-91), PrP(90-126) together with H111A and H96A analogues of PrP(90-126) and small penta-peptides, PrP(92-96) and PrP(107-111). All of these PrP fragments use the human sequence number reference. 
The following are the two Aβ peptides that are discussed in this thesis. These protein samples were synthetically produced by Zinsser Analytic (UK) Ltd.
Aβ (1-42)
DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV IA
Aβ (1-40)
DAEFRHDSGY EVHHQKLVFF AEDVGSNKGA IIGLMVGGVV
The following PrP fragments were synthetically produced by ABC Imperial College. The following peptides were acetylated and amidated to mimic full length PrP. All the following are from the human prion protein sequence.
hPrP(58-91)
GQPHGGGWGQ PHGGGWGQPH GGGWGQPHGG GWGQ
hPrP(90-126)
GQGGGTHSQW NKPSKPKTNM KHMAGAAAAG AVVGGLG
hPrP(90-126) H96A
GQGGGTASQW NKPSKPKTNM KHMAGAAAAG AVVGGLG
hPrP(90-126) H111A
GQGGGTHSQW NKPSKPKTNM KAMAGAAAAG AVVGGLG
hPrP(91-115)





2.02.3 Recombinant Protein and Fragments
The coding region of the full-length mouse PrP(23-231) was cloned into a pET-23 vector to produce a tag-free protein as previously described. Expression and purification is identical to previously described procedures (). In addition recombinant protein containing the unstructured part of PrPC only, mPrP(23-126) and the structured part of the prion protein, PrP(113-231), were also expressed and purified using the same process.  Comparisons of Cu2+ binding with previous studies were made using visible-CD which is very diagnostic of the binding (). In the text when referencing PrP sequence numbers I am referring to the mouse sequence unless otherwise mentioned. Smaller fragments use the human numbering system while the full length PrP and the N-terminal fragment uses the mouse numbering system.
The following protein samples were made recombinantly within Professor David R. Brown’s group from the University of Bath. The following protein samples are from the mouse sequence.
mPrP(23-231)




KKRPKPGGWN TGGSRYPGQG SPGGNRYPPQ GGTWGQPHGG GWGQPHGGGW GQPHGGGWGQ PHGGGWGQGG GTHSQWNKPS KPKTNMKHVA          GAAAAGAVVG         GLGG
mPrP(113-231)
GAAAAGAVVG GLGGYMLGSA MSRPMIHFGN DWEDRYYREN MYRYPNQVYY RPVDQYSNQN NFVHDCVNIT IKQHTVTTTT      KGENFTETDV            KMMERVVEQM          CVTQYQKESQ           AYYDGRRSS
2.02.4 Equipment and Software
The following is a list of all the equipment and software used to generate the data present in this thesis. 
Table 2.0 3: List of Equipment used Throughout the Thesis
Equipment	Manufacturer	Model	Software
Circular Dichroism Spectrometer	Applied PhotoPhysics	Chirascan	Applied Photophysics Ver: 4.2.0
96-Well Plate Fluorescence Reader	BMG	FluoStar Galaxy	FluoStar Galaxy Ver: 4.31.0
Fourier Transform Infrared Spectrometer	Bruker	IFS 66/s	OPUS Ver: 3.1 andOMNIC Ver: 2.11 
Gel Filtration Chromatography	GE Healthcare	ÄKTA FPLC	UNICORN Ver: 4.00.16
Nuclear Magnetic Resonance Spectrometer	Bruker	AV 600AV 700	TOPSPIN Ver: 2.0.bXWINPLOT Ver: 4.4.0.0
Ultraviolet-Visible Spectrometer	Hitachi	U-3010	UV Solutions Ver: 2.0
(Data Analysis software)	Synergy Software 	-	KaleidaGraphVer: 4.01




Methods used throughout the thesis are described here. The methods that are particular to each chapter are described in a short section in each chapter.
2.03.1 Buffers
UHQ water (10-18 Ω-1cm-1 resistivity) was used throughout. The pH was measured before each experiment. Some experiments required the use of buffers to maintain the pH. Unless specified the pH was adjusted using small aliquots of 10 mM NaOH or HCl. Cu2+ titrations of PrP(91-96), PrP(107-111) and PrP(90-126) were all carried out in the absence of buffer, the peptide sample were found to be sufficiently self-buffering to maintain a stable pH during the course of the experiments. 
2.03.2 Absorbance (UV/Vis) Spectroscopy
Protein and peptide concentrations were determined using an extinction coefficient at 280 nm, which is the sum of the extinction coefficients for the total number of aromatic residues and disulfide bonds (). This gave an extinction coefficient of 62,280 M-1cm-1 at 280 nm for full-length mPrP(23-231). UV/visible absorption spectra were obtained with a double beam spectrophotometer, using a 1 cm path-length.  In the case of pentapeptides which lacked aromatic residues, the weight was used to approximate the concentration and 20 % water content was assumed.
2.03.3 Circular Dichroism (CD) Spectroscopy
Far-UV-CD. Typically, spectra were recorded between 185 and 260 nm, with sampling points every 0.5 nm. Three scans were recorded and a baseline spectrum was subtracted from each data set. Quartz cells with 0.1 cm path-length were used.  Data were processed using Applied Photophysics Chirascan Viewer, Microsoft Excel and the KaleidaGraph spreadsheet and graph package. The direct CD measurements (θ, in millidegrees) were converted to molar ellipticity,  (M-1cm-1), using the relationship  = θ/33,000  c  l, where c is the concentration and l is the path-length, as previously described in section 2.1.4.  It is normal practice to zero UV-CD signal between 250-260 nm, however, for some data the baseline offset has not been corrected as appreciable signal is observed in this region.  
Visible CD. Measurements were made between 300-780 nm, this region is diagnostic of Cu2+ binding to protein, in this case to PrPC (). Protein concentration should be between 50 -100 µM and a 1 cm path-length cuvette should be used.
2.03.4 Folding Stability Studies 
Unfolding. CD spectra were recorded on an Applied Photophysics Chirascan instrument using 0.1 cm path-length.  Unless specified otherwise, the protein stocks were prepared typically at 5 μM concentration in 30 mM buffer.  A range of urea concentrations up to 10 M urea were used while the CD spectra were recorded at 225 nm and 260 nm, unless specified all denaturations were carried at 25˚C. Typically, sixty different urea concentrations were used, equally distributed between 0 and 10 M urea. Titrations were performed by combining two PrP preparations one in 10 M urea with buffer and the other with identical protein concentration in buffer (no denaturant). This approach maintains a constant protein concentration with addition of urea. Once the two 5 µM PrP stock samples had been made (PrP no urea and 10 M urea in 30 mM buffer).
Refolding. Refolding experiments were performed by serial dilution of the 10 M urea PrP with increasing amounts of buffer (30 mM). Similar approaches were used for the GdmCl unfolding and refolding titrations. 
The folding/unfolding transition is rapid for PrPC (within milli-seconds) () and equilibrium in the presence of urea was reached rapidly, as judged by identical repeats of CD scans recorded over time.  Samples were left for an hour to reach equilibrium before recording the CD spectrum. 
The thermal unfolding was studied but this technique is irreversible; therefore, extraction of thermodynamic properties would be inaccurate and was not possible. Thermal unfolding studies were used to provide further evidence of stability.
CD spectra collection. Spectra were recorded between 115 and 265 nm, with sampling points every 20 nm. Three scans were recorded and a baseline spectrum was subtracted from each data set. Quartz cells with 0.1 cm path-length were used. Data points collected at 225 nm were used to produce the folding curves, while those collected at 265 nm were used to zero the data. All CD data were processed using Applied Photophysics Chirascan Viewer, Microsoft Excel and the KaleidaGraph spreadsheet and graph package. 
Curve Fitting. The urea denaturation curves were fitted to a modified Hill equation, equation 6 (eq 6) 
						(eq 6)
Where y is CD signal, ydiff = ymax-ymin, [D] is the concentration of urea, [D50% ] is the concentration of urea at the midpoint of the folding transition and n is the Hill coefficient ().
Thermodynamic Calculation. The equilibrium constant (K) for unfolding at each urea concentration was calculated from the denaturation curve as using the equation below (eq 7)
				(eq 7)
Using ymin as fully folded and ymax as fully unfolded. 
The Gibbs free energy of unfolding at a particular urea concentration is given by
								(eq 8)
Where R is the gas constant (8.314  J K-1 mol-1) and T is the temperature, 298 K. A plot of ΔG versus urea concentration reveals a linear relationship; extrapolation of the line to where urea is at zero concentration gives the free energy of unfolding in the absence of urea (ΔGUH2O).  The gradient of the line (m) is a measure of the cooperativity of the folding transition.  Inherent errors associated with ΔGUH2O makes the difference in ΔG at the folding transition midpoint (ΔΔGU[D]50%) a more appropriate parameter to measure stability.
The difference in stability of unfolding control and experiment conditions (ΔΔGU[D]50%) is given by equation 9 (eq 9), ().
			(eq 9) 
2.03.5 Fourier Transform Infra-Red (FT-IR) Spectroscopy 
Spectra were obtained using a Bruker IFS 66/s FT-IR-spectrometer. Spectra represent an average of 32 scans, recorded at 25 ºC in the spectral range from 3000 cm-1 to 370 cm-1. All samples were prepared in water unless described otherwise. Small amounts (5 μl) of sample were aliquoted onto the ATR crystal (ZnSe prism) where it was purged with nitrogen gas to generate a protein film.

2.03.6 Gel Filtration Chromatography
The Tricorn Superdex 75 10/300 and Superdex 200 10/300 analytical gel filtration chromatography columns (GE Healthcare) were used, on an automated AKTA FPLC system (GE Healthcare), at a flow rate of 0.5 mL min-1. The column was equilibrated with 1.5 column volume of buffer, at 4°C. An 0.5 mL injection volume was used to load the protein onto the column.
The molecular weight of the protein was estimated using calibration samples of known molecular weight. The following equation was used for the preparation of the calibration curve: 

									(eq 10)         
where Kav is the partition coefficient, Vo is the column void volume (the elution point of blue dextran), Ve is the elution volume of a protein and Vc is he geometric column volume (which can either be worked out by; r2 x π x l where r is the radius and l is the column length or alternatively it is the elution volume of acetone). 
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3.01 Abstract












The misfolding of the prion protein (PrPC) is central to Prion disease; Cu2+-induced changes in main-chain structure are therefore of particular interest. While, many studies have been directed at the coordination geometry  ADDIN EN.CITE (; ) of the various binding modes to PrPC and their affinities for Cu2+ ions (), there have been surprisingly few detailed studies directly investigating the structural changes induced by Cu2+ ions binding to PrPC. The flexible nature of the Cu2+ binding domain of PrPC has hampered crystallographic studies, while the paramagnetic nature of the Cu2+ ions has restricted solution NMR studies.  Thus, NMR studies have been limited to low substoichiometric levels of Cu2+ ions (<0.1 mole equivalents), which cause a profound paramagnetic broadening of resonance close to the paramagnetic centre (). Consequently, studies investigating the influence of Cu2+ ions on the main-chain conformation of PrPC have been limited to UV-CD  ADDIN EN.CITE (; ) and Raman () spectroscopic investigations of small PrP fragments.  Similarly, studies on full-length mammalian PrPC, have been limited to Raman optical activity (ROA) () and UV-CD  ADDIN EN.CITE (; ) approaches.  These studies have been performed in the presence of excess Cu2+ ions.  Although, fragments from the unstructured N-terminal domain of PrPC represent a good model for Cu2+ binding to full-length prion protein (), no study has attempted to relate structural transitions observed in fragments of the protein to those observed in full-length PrP.
The folding and stability of wild type PrPC and PrP mutants have been studied by a number of groups  ADDIN EN.CITE (; ; ; ; ).  Unfolding at pH 7 has been described essentially as a simple two state process, the folding is very fast, as expected of a small α-helical protein, and is fully reversible in chemical denaturants ().   I am not aware of any reports on the effect of Cu2+ ions on the folding stability of PrPC.
The aim is to investigate the effects of Cu2+ ions on the secondary structure of PrPC. Here, I relate the Cu2+ induced changes in the secondary structure for small fragments in the amyloidogenic region and the octarepeats region of PrPC, to Cu2+ bound full-length PrP(23-231). I also investigate the effect of Cu2+ ions on the folding stability of PrPC upon chemical denaturation, and show that Cu2+ binding to PrP(23-231) has an appreciable destabilising effect on the native fold of PrPC.


3.03 Materials and Methods 
For a detailed description of the techniques and protocols used, refer to chapter 2.
3.03.1 Urea Denaturation Studies  
CD spectra were recorded using a 0.1 cm path-length. PrP(23-231) was prepared typically at 5 μM concentration in 30 mM ethylmorpholine (EM) buffer at pH 7.5.  For the unfolding, a range of urea concentrations up to 10 M urea were used, the experiments were carried out at 25 ˚C. Apo-PrPC and Cu2+-loaded-PrPC experiments were performed using the same urea stock solutions. Refolding experiments were performed by serial dilution of the 10 M urea PrPC stock with increasing amounts of EM buffer, maintained at 30 mM concentration.  Similar approaches were used for the GdmCl unfolding and refolding titrations. For details on CD parameters and fitting folding curves refer to chapter 2.03.4. 
3.03.2 Circular Dichroism (CD) 
The baseline spectra were subtracted from each spectrum. Quartz cells with a 0.1 cm path-length were used. It is normal practice to zero far-UV-CD signal between 250 and 260 nm, however, for some data, the baseline offset has not been corrected as appreciable signal is observed in this region. The subtle dilution effect observed in the CD spectra of Figure 3.11a was corrected for by normalising the data. Concentration correction based on the absorption signal at 280 nm gave similar dilution factors; however, I found that the most appropriate approach to correct for the dilution effect was to normalise the signal for the helical content, as it is clear that Cu2+ ions addition (up to 6 mole equivalents) does not affect the helical content in the C-terminal domain. I chose to normalise the signal at 230 nm, as this wavelength gave an appreciable CD signal for α-helix and, in addition, Cu2+-induced changes do not influence the CD spectra at this wavelength. The Vis-CD measurements were recorded, between 300-780 nm, diagnostic of Cu2+ binding to PrP. Quartz cells with 1 cm path-length were used for Vis-CD.
3.03.3 Titrations: 
Small aliquots of fresh aqueous solutions were used to add metal ions (Cu2+ as CuCl2.2H2O typically 25 mM solutions). CuCl2 dissolved directly into water is highly soluble at this mildly acidic pH. Typically, Cu2+ titrations for peptide fragments were carried out in the absence of buffers to avoid competition with Cu2+ ions by the buffer and light absorption in the far-UV region. Recombinant PrP samples contained sodium acetate (NaOAc) buffer and small amounts of (0.0005 %) sodium azide. Protein and peptide concentrations were determined using an extinction coefficient at 280 nm (). In the case of penta-peptides lacking aromatic residues, the weight was used to approximate the concentration, and 20 % water content was assumed. Typically, Cu2+ titrations for peptide fragments were carried out in the absence of buffers to avoid competition with Cu2+ ions by the buffer and light absorption in the far-UV region.  


3.04 Results and Discussion
3.04.1 Cu2+ and the Folding Stability of PrPC
Prion diseases involve the partial or complete unfolding of the cellular form of PrP (PrPC). I therefore wanted to establish if Cu2+ ions affect the folding stability of PrPC. Here, I have used the chemical denaturant urea to monitor Cu2+-loaded and apo-PrP(23-231) folding stability. The CD signal at 225 nm, which is very diagnostic of α-helical content, was monitored over a range of urea concentrations. Urea unfolding curves for PrP(23-231) loaded with 1 and 6 mole equivalents of Cu2+ ions are compared in Figure 3.01 relative to apo-PrP(23-231).
The urea concentration at the mid-point of unfolding ([D]50%) for apo-PrP(23-231) is 5.79 ± 0.04 M, at pH 7.5.  This is in agreement with previous apo-PrPC urea unfolding studies.  The [D]50% value for PrP(23-231) with 1 mole equivalent of Cu2+ ions present is reduced to 5.06 ± 0.03 M urea, also at pH 7.5. The [D]50% value for Cu6PrPC (PrPC loaded with six mole equivalents of Cu2+ ions) is also reduced, to a slightly lesser extent (5.19 ± 0.04 M). The inset in Figure 3.01 shows a linear relationship between the free energy of unfolding and urea concentration; this can be used to extrapolate the free energy of unfolding at zero urea concentration (ΔGUH2O) and the folding cooperativity.  From the folding cooperativity, the free energy difference at the folding midpoint (ΔΔGU[D]50%) for apo- and Cu2+-loaded-PrP(23-231) may be calculated (see experimental, chapter 2, section 2.03.4).  Table 3.01 summarises the thermodynamic unfolding parameters. It is clear that 1 mole equivalent of Cu2+ ions binding to PrP(23-231) significantly destabilises the native fold of the protein by 2.02 ± 0.05 kJmol-1 (ΔΔGU[D]50%).  The addition of 6 mole equivalents of Cu2+ ions also destabilises the native fold of the protein by a similar amount, 1.66 ±  0.05 kJmol-1.  The 


Figure 3.0 1: Urea Denaturation of PrP(23-231) with and without Cu2+
a) 1 mole equivalent of Cu2+ ions (●), 6 mole equivalents of Cu2+ ions (○) and Apo PrP(23-231) (●).  Folded fraction based on ∆e at 225 nm with increasing [urea]. Inset, ∆G (Jmole-1) as a function of [urea]. b) [Urea] at the midpoint of the folding transition. At pH 7.5, 5 μM PrP(23-231) in 30 mM EM buffer at pH 7.5 and 25 ºC. 

Table 3.0 1: Thermodynamic Folding Stabilities

  PrP(23-231) with and without Cu2+ ions at pH 7.5 and 25 ºC.  Standard errors are shown. 
.

folding cooperativity for apo and Cu1PrP are very similar. This urea unfolding experiment was repeated and the same trend was observed with Cu2+ ions destabilising the fold of PrPC, as shown in Figure 3.02 and Table 3.02.
The Cu2+-induced destabilisation of PrPC is slightly more pronounced for 1 relative to 6 mole equivalents of Cu2+ ions.  It is notable that 1 mole equivalent of Cu2+ ions has no significant effect on the solubility of PrPC, under these conditions.  This is apparent from the CD signal at 225 nm, which has the same signal intensity in the presence and absence of 1 mole equivalent of Cu2+ ions, for fully folded PrPC, as shown in Figure 3.03.  However, the addition of 6 mole equivalents of Cu2+ ions does cause a 10 % drop in the CD signal, this suggests some Cu2+-induced precipitation at the higher levels of Cu2+ ions. This precipitation may mask the effect of the Cu2+ induced destabilisation of the native fold and might explain the small difference in the [D]50% for the 1 and 6 mole equivalents of Cu2+ ions.
Urea unfolding of apo-PrPC is reversible and undergoes a simple two-state folding transition  ADDIN EN.CITE (; ; ; ; ), this is shown in Figure 3.04.  I confirmed that Cu2+-loaded PrP(23-231) also undergoes reversible urea unfolding.  This was achieved by a serial dilution of Cu2+-loaded-PrP(23-231) preparations, from a PrP sample with 10 M urea present (unfolded) down to below 1 M urea (refolded). The reversible unfolding of Cu1PrPC is shown in Figure 3.05.  Again, the [D]50% value indicates that 1 mole equivalent of Cu2+ destabilises the native fold of PrP. Like the unfolding experiment, the refolding traces indicate that PrP loaded with 6 mole equivalents of Cu2+ ions have less  of  a  destabilising  effect  than  just  1 mole equivalent. The spectra suggest that with 6 equivalents of Cu2+ ions there is some aggregation of PrP as the total CD signal is reduced relative to Cu1PrPC and apo data.


Figure 3.0 2: Urea Denaturation of  PrP(23-231) with and without Cu2+ (Repeat Measurement)
a) 1 mole equivalent of Cu2+ ions (●), 6 mole equivalents of Cu2+ ions (○) and Apo PrP(23-231) (●).  Folded fraction based on ∆ε at 225 nm with increasing [urea]. Inset, ∆G (Jmole-1) as a function of [urea]. b) [Urea] at the midpoint of the folding transition. With 13 μM PrP(23-231) with 30 mM EM buffer at pH 7.4 and 25 ºC were used. 

Table 3.0 2: Thermodynamic Folding Stabilities









Figure 3.0 3: Urea Denaturation of PrP(23-231) with and without Cu2+ Ions












Figure 3.0 4: Urea Unfolding and Refolding of Apo-PrP(23-231)











Figure 3.0 5: Urea Refolding of PrP(23-231) with and without Cu2+
 Apo (black unfilled circles), with 1 mole equivalent of Cu2+ ions (blue filled circles). Direct ∆ε values are shown. PrP at 4.3 μM in 30 mM EM at pH 7.5 and 25 ºC were used. Refolding of Cu1PrP is fully reversible compared to apo-PrP. The [D]50% is 5.47 ± 0.05 M compared to 5.87 ± 0.06 M for apo-PrP.


Urea does not compete for Cu2+ ions even at the molar concentrations used, Cu2+ remains fully bound to PrPC.  This was confirmed by monitoring the highly diagnostic Cu2+ Vis-CD signals for Cu1PrP(58-91) in the presence of urea, as shown in Figure 3.06.  I repeated the folding stability studies using a second chemical denaturant, guanidinium chloride (GdmCl); in contrast to urea, this molecule competes very effectively for Cu2+ ions bound to PrPC.  As a consequence, I could not use it to monitor the effect of Cu2+ ions on the stability of the PrPC fold.  Figure 3.07 shows, using Vis-CD to detect the Cu-PrP complex, GdmCl will rapidly remove Cu2+ ions from the natively unstructured domain of PrPC.  As would be expected, with the use of GdmCl, there is no difference in the stability of PrP in the presence and the absence of Cu2+ ions.  I note that Cu2+ binding to PrP, and possible precipitation of the protein had no effect on the subsequent GdmCl unfolding curves, as shown in Figure 3.08. Thermal denaturation of PrPC in the absence and presence of Cu2+ ions was also measured using far-UV-CD. The measurements suggest that Cu2+-loaded-PrPC is destabilised relative to apo, as shown in Figure 3.09, although, thermal denaturation of PrPC was found to be non-reversible.







Figure 3.0 6: Urea does not Compete for Cu-PrP Binding











Figure 3.0 7: Guanidinium Chloride Competes for Cu-PrP Binding










Figure 3.0 8:  Guanadinium Chloride Denaturation of PrP(23-231) with and without Cu2+ Ions





Figure 3.0 9: Thermal Denaturation of PrP(23-231)
Thermal denaturation of a) PrP(23-231) alone and b) PrP(23-231) in the presence of 6 mole equivalents of Cu2+ ions. c) In the absence of Cu2+ (black filled circles) and in the presence of 6 mole equivalents of Cu2+ ions (black filled diamonds). Cu6PrP is destabilised relative to PrPC alone; 50 ºC relative to 59 ºC. Thermal unfolding is not reversible so the unfolding curves may well be influenced by aggregation to different extents. Peptide at 10 μM was used at pH 7.5 and 25 ºC.
enthalpic stabilising interaction in or between the unstructured domain and the C-terminal α-helical domain may be lost with Cu2+ ions binding to the amyloidogenic region. Clearly, the ability of Cu2+ ions to destabilise the native fold of PrPC has implications for protein misfolding and is discussed later.
3.04.2 The Unstructured N-Terminal Domain, PrP(23-126) 
Next, I wanted to characterise the influence of Cu2+ ions on the secondary structure of PrPC.  There is extensive evidence to indicate that, in terms of coordination geometry and affinity, Cu2+ ions bind to fragments from the N-terminal unstructured domain of PrPC similarly to those from the full-length protein  ADDIN EN.CITE (; ). Thus, small fragments of the N-terminus represent a good model for Cu2+ coordination to full-length PrPC.  I wanted to establish if the Cu2+ induced secondary structure changes to the whole of the unstructured N-terminal domain, PrP(23-126), could be directly related to Cu2+ binding to smaller fragments from the octarepeat and amyloidogenic regions. Figure 3.10a presents the Cu2+ titration by CD in the UV region of, the mouse sequence, mPrP(23-126). This PrPC domain has an irregular structure in the absence of Cu2+ ions, with a single negative CD band at 198 nm. As Cu2+ is added to mPrP(23-126), there is a reduction in the intensity of a negative band at 198 nm, which suggests a loss of irregular structure together with the appearance of a negative signal at 221 nm. 
The Cu2+-induced changes in secondary structure from PrP(23-126) can be compared to the effect of Cu2+ ions on the smaller octarepeat fragments and the peptide fragments from the amyloidogenic region, as described in the following sections. The Cu2+-associated changes in secondary structure are most apparent in the apo-subtracted difference spectra shown in Figure 3.10b, which highlights the changes in conformation upon Cu2+ addition. The effect of Cu2+ addition on the unstructured N-terminal domain chocolate 


Figure 3.1 0: Cu2+ Binding to the Unstructured Domain, PrP(23-126)
a) UV-CD spectra for Cu2+ titration, showing additions from ~0.5 mole equivalents up to 9 mole equivalents of Cu2+ ions with PrP(23-126). Inset, binding curves at 201 nm and 221 nm. b) Difference (apo subtracted) spectra of the Cu2+ titration. Inset, comparison of the unstructured domain, PrP(23-126), with 6 mole equivalents of Cu2+ ions (solid line) to the octarepeats region, PrP(58-91), with 4 mole equivalents of Cu2+ ions (dashed line). (pH 7.4, with 20 μM peptide). Changes in CD spectra with Cu2+ additions to the N-terminal, natively unstructured domain, are comparable to those observed for the octarepeat region. (Data obtained by Mark Klewpatinond).

is strikingly similar to that of the shorter octarepeat fragment.  In particular, both spectra show the appearance of a negative band at 221 nm, while the initially negative band at 200 nm becomes increasingly more positive. The position of the CD bands and the intensities of the bands are comparable, as highlighted by the insert, Figure 3.10b, showing the overlaid apo-subtracted spectra of the two PrPC fragments (residues 23-126 and 59-90).  
Binding curves at 200 nm, also shown in Figure 3.10a, indicate a gradual loss of random coil structure, as up to ~6 mole equivalents of Cu2+ ions are added. The behaviour of the 221 nm band is more complicated; the first equivalent of Cu2+ ions has little effect at this wavelength, and the negative band (at 221 nm) then becomes more negative in intensity as up to ~5 mole equivalents of Cu2+ ions are added. This behaviour is consistent with what is known about the sequential loading of Cu2+ to PrPC (): the initial Cu2+ ions binding to His95 and His110 (His96 and His111 in the human sequence), followed by the change in CD signal characteristic of binding to the octarepeats. Further additions of Cu2+ ions beyond 6 mole equivalents cause a general loss of intensity, attributed to protein precipitation.
The dominant changes observed in the CD spectra for the full unstructured domain of PrPC are due to the binding of Cu2+ ions to the octarepeat region.  This observation agrees with the relative intensity of changes in the CD bands with Cu2+ addition for the amyloidogenic and the octarepeat regions.  Specifically, the maximal  change in Δε  for the amyloidogenic fragment is -19 M-1cm-1 at 217 nm, while for the octarepeat fragment, changes in Δε are much larger; 45 M-1cm-1 at 200 nm and -40 M-1‑cm-1 at 221 nm.

3.04.3 Cu2+ Binding to Full-Length PrP(23-231)
A Cu2+ titration using UV-CD was carried out on full-length PrP(23-231), as shown in Figure 3.11. Spectra are dominated by the α-helical CD bands from the C-terminal domain; hence, Cu2+-induced changes in conformation at the octarepeat region are much less apparent.  Indeed, at first glance the addition of as much as 6 mole equivalents of Cu2+ ions causes almost no change in the UV-CD spectra, Figure 3.11a. A closer inspection suggests that there is some small loss in signal. Determination of the UV-absorption at 280 nm indicates that the small loss of signal can be attributed to some minimal precipitation.  However, not all bands are reduced in intensity to the same extent. This indicates that Cu2+ ions have a conformational effect over and above causing some minimal precipitation. In an attempt to isolate this effect from the general loss of signal, the Cu2+ loaded spectra have had a concentration correction performed on their intensities (see section 3.03.2). 






Figure 3.1 1: Cu2+ Titration with PrP(23-231)
a) UV-CD spectra of PrP(23-231), apo (black line) and with up to 6 mole equivalents of Cu2+ ions (grey line). b) spectra from a) normalised to apo at 230 nm. c) Apo subtracted normalised difference spectra. Inset, comparison of full length, PrP(23-231) with 6 mole equivalents of Cu2+ ions (black line) to the octarepeats fragment, PrP(58-91), with 4 mole equivalents of Cu2+ ions (dashed line). Full-length PrP is dominated by CD band for the C-terminal α-helices. The changes in the CD spectra are similar to those observed for the octarepeats. PrPC used at 6.5 μM at pH 7.4 and 25 ºC.


This study shows, with the addition of up to 6 mole equivalents of Cu2+ ions, Cu2+ binding does not directly cause the α-helical part of PrPC to unfold at room temperature. As is also apparent for the N-terminal domain PrP(23-126), I have been able to relate changes in structure for full-length PrPC to the smaller fragments. In particular, the changes observed in the octarepeat fragment with Cu2+ addition are comparable to those observed in full-length PrPC. 
Excess Cu2+ ions were titrated into PrPC, to investigate the effect this would have on the folding. Figure 3.12a shows the far-UV-CD spectra of PrP(23-231) with 6, 10 and 16 mole equivalents of Cu2+ ions. There is a significant loss of the CD signal. By 16 mole equivalents of Cu2+ ions the band at 222 nm has halved in intensity while the band at 208 nm has lost even more intensity. The band at 190 nm drops in intensity by two thirds. These changes suggest that not only is there general precipitation of PrPC but also an increase in random-coil character. If the changes in the spectra were only due to precipitation, all signals would decrease in intensity by the same proportion. The appearances of the CD bands do not indicate a significant increase in β-sheet as a strong positive CD band at 198 nm is not observed.








Figure 3.1 2: Far-UV-CD and FT-IR of PrP(23-231) with Excess Cu2+ Ions




There have been surprisingly few studies describing the changes in PrPC main-chain in the presence of Cu2+ ions.  Studies on fragments of PrP have been limited to far-UV-CD studies  ADDIN EN.CITE (; ), in addition the binding mode of Cu2+ ions in the octarepeat region has been probed using Raman spectroscopy (). Previous studies on full-length PrPC have included either the refolding PrPC in the presence of excess Cu2+ ions  ADDIN EN.CITE (; ) or adding 10-100 mole equivalents of Cu2+ ions to PrPC  ADDIN EN.CITE (; ). These data, using Raman Optical Activity (ROA) and UV-CD  ADDIN EN.CITE (; ), are consistent with the loss of α-helix observed in my own far-UV-CD studies, but only when excess Cu2+ ions are added, shown in Figure 3.12a.   In particular, the Cu2+-refolded PrP showed significant loss in the α-helical and polyproline-II structures, concomitant with an increase in the irregular and disordered structure (). 
3.04.4 The Octarepeat Region, PrP(58-91) 
Here, I describe the Cu2+-induced structural changes in small fragments of PrP, notably the octarepeat region.  Figure 3.13 displays the UV-CD data for the Cu2+ titration of mPrP(58-91) (mouse sequence). The octarepeat region has an irregular structure in the absence of Cu2+ ions, which is indicated by the negative CD band at 198 nm. There is also a weak positive band at 225 nm assignable to some polyproline-II character () present in this predominantly flexible and irregular structure. Addition of Cu2+ ions causes profound changes in the appearance of the UV-CD spectra. In particular, there is a reduction in the negative band at 198 nm and the appearance of two new bands: one positive band at 200 nm and one negative band at 221 nm. An identical effect has previously been reported for the human PrPC sequence within the octarepeat region  ADDIN EN.CITE (; ). Contributions from the Trp side-chain can give rise to the negative signal at 221 nm, while, main-chain amide gives rise to the positive signal at 200 nm. The change in structure saturates close to 4 mole equivalents of Cu2+ ions, reflecting the four imidazole binding sites.
Furthermore, after careful inspection of the apo-subtracted spectra, Figure 3.13b, it is clear that there is more than one mode of Cu2+ coordination. The first mole equivalent of Cu2+ ions produces a weak positive CD signal at 208 nm. With subsequent additions of Cu2+ ions, an isodichroic point becomes apparent at 211 nm. The positive band at 200 nm and a negative band at 221 nm appear only after 1 mole equivalent of Cu2+ ions is added. At 4 mole equivalents of Cu2+ ions, there are no further changes. These observations tie in very well with what is known about the two binding modes of the octarepeats region. The first equivalent of Cu2+ ions forms a multiple-histidine (His) complex, as described in chapter 1, Figure 1.04b. Subsequent additions of Cu2+ ions cause this binding mode to be replaced by a coordination mode involving individual His residues, also shown in Figure 1.04c. This bimodal binding has previously been detected using potentiometry, EPR and Vis-CD  ADDIN EN.CITE (; ; ).
3.04.5 The Amyloidogenic Region, PrP(90-126)








Figure 3.1 3: Cu2+ Binding to the Octarepeat Fragment, PrP(58-91)
a) Far-UV-CD spectra of the Cu2+ titration with PrP(58-91), showing up to 6 mole equivalents of Cu2+ ions. b) Difference spectra of the Cu2+ titration. Cu2+ ions bind to the 4 octarepeats fragment, CD bands at 201 nm and 221 nm saturate when 4 mole equivalents of Cu2+ ions are added. Peptide used at 20 μM, pH 7.4 and 25 ºC (Data obtained by Mark Klewpatinond). 


I postulated that the increase in -sheet like CD spectra observed in the amyloidogenic region of PrPC could be the result of one of three possibilities, as summarised in Figure 3.14a-c: Configuration 1, Cu2+ coordination to the individual binding sites at His96 and His111 causes changes in main-chain conformation; Configuration 2, a single Cu2+ ion is coordinated by both His96 and His111, which causes the peptide to form an anti-parallel -hair pin;  Configuration 3, Cu2+ coordination causes intermolecular self-association and aggregation, causing extended structures to form.  Here, I outline a series of far-UV-CD experiments that probe the relative likelihood of these three possible conformations.
Comparison of Cu2PrP(90-126) with Pepta-petides. In Figure 3.15, I compared the Cu2+-induced changes in the CD spectra of PrP(90-126) with those of the two penta-peptides; PrP(92-96) and PrP(107-111). These penta-peptides are the smallest binding motifs for the two Cu2+ binding sites identified in the amyloidogenic region of PrPC  ADDIN EN.CITE (; ; ; ; ).  I wanted to determine if the changes observed in the CD spectra of PrP(90-126) could be deconvoluted from the sum of changes in smaller fragments from this region, with the aim of understanding the reasons behind the changes observed in the CD spectra. The difference (apo-subtracted) spectra are shown to emphasise the direct effects of Cu2+ ion addition.  The molar ellipticity spectra are shown in Figure 3.16.
Figure 3.16, shows the UV-CD spectra for the Cu2+ titration with PrP(90-126). Changes in the secondary structure are apparent with Cu2+ additions in the CD spectra. In particular, the gradual loss of intensity in the negative CD band at 198 nm is observed with increasing Cu2+ ion additions; together with this is the appearance of a chocolate

Figure 3.1 4: Copper Binding Configurations
Schematic of the three possible configurations induced by Cu2+ binding in the amyloidogenic region, PrP(90-126). a) Cu2+ coordination to the individual binding sites at His96 and His111 causes changes in main-chain conformation. b) A single Cu2+ ion is coordinated by both His96 and His111, which causes the peptide to form an anti-parallel -sheet and -turn. c) Intermolecular self-association/aggregation causes extended structures. Residue numbers shown are for human PrP.


Figure 3.1 5: Comparison of Far-UV-CD Spectra of Cu2+ Titration for PrP(90-126) with Penta-Peptides









Figure 3.1 6: Amyloidogenic Region






negative band at 217 nm. There is also the appearance of a weak CD band at 250 nm. The loss of signal at 198 nm, suggests the loss of the irregular character of PrP(90-126) peptide with the addition of Cu2+ ions, while a negative CD band at 217 nm is often assigned to an increase in extended β-sheet like structure.   
Figure 3.16b, shows the far-UV-CD spectra of PrP(92-96), a penta-peptide, with up to 1.4 mole equivalents of Cu2+ ions. Increasing additions of Cu2+ ions cause the appearance of the two CD bands, at 210 nm and 242 nm. The change in ∆ε at 210 nm observed shows that the signal plateaus at ~0.9 mole equivalents of Cu2+ ions. However, for the ∆ε at 242 nm a slightly different behaviour is observed, with the change in the signal completing at ~0.7 mole equivalents of Cu2+ ions.  The increase in intensities of the CD bands at 210 nm and 242 nm, imply that in the presence of Cu2+ ions there is a change in the secondary structure of the penta-peptide, PrP(92-96). The band at 213 nm is dominated by electron transition associated with the amide bond influenced by main-chain conformation, while the band at 242 nm may be due to ligand-to-metal charge-transfer. There appears to be no change in the spectra after the addition of 1 mole equivalent of Cu2+ ions, suggesting the penta-peptide is fully saturated. The discrepancies in the behaviour of the peptide at 242 nm and 210 nm suggest there is more than one mode of binding. It is possible that at low Cu2+ ion levels the two peptide molecules bind to a single Cu2+ ion, but as the levels of Cu2+ are raised, a 1:1 complex dominates.
A similar Cu2+ titration was carried out on the other penta-peptide, PrP(107-111). Figure 3.16c, shows the UV-CD spectra of the Cu2+ titration with PrP(107-111). The changes in the CD spectra, with increasing levels of Cu2+ ions, are quite different to those observed for PrP(92-96), with an increase in intensity of a negative band at 217 nm, and a loss of a negative band at 198 nm. In addition there is an increase of a broad band at ~250 nm.  The peptide displays very similar binding curves at two wavelengths (250 nm and 217 nm) with a clear saturation at 1 mole equivalent of Cu2+ ions. 
For both penta-peptides there are no further changes in the CD spectra beyond the addition of 1 mole equivalent of Cu2+ ions, indicating are fully saturated. This 1:1 stoichiometry is in agreement with the Vis-CD studies and 1D 1H NMR studies previously described  ADDIN EN.CITE (; ).  The changes in the far-UV-CD spectra for PrP(92-96) are less marked than those observed for the other penta-peptide with relatively weak, Cu2+-induced, CD signals at 210 nm and 242 nm. It has been shown by EPR and 1D 1H NMR that these two peptides form very similar square-planar complexes  ADDIN EN.CITE (; ). It is possible to account for this difference in appearance in the CD spectra by looking at the primary sequence, PrP(92-96) contains a number of glycine (Gly) residues (GGGTH) that are non-chiral and so will not contribute to the CD signal.
The dominant feature of the spectra, seen in Figure 3.15a and 3.15b, is the appearance of a negative CD band at 217 nm for PrP(90-126) and PrP(107-111), this is often attributed to β-sheet formation, together with a loss of a negative CD band at 198 nm, which is associated with a loss of irregular structure.  The inset to Figure 3.15a  highlights the stoichiometric loading of Cu2+ ions, and the changes in the intensities of the signal plateau after 2 mole equivalents of Cu2+ ions are added to PrP(90-126), implying a 2:1 binding stoichiometry. This is in agreement with other studies showing Cu2+ ions can bind independently to the two His residues (96 and 111) within the amyloidogenic region  ADDIN EN.CITE (; ).  
In the last panel, Figure 3.15d, I directly relate the Cu2+-induced spectral changes in PrP(90-126) to those observed for the penta-peptides. Figure 3.15d shows the two Cu2+-loaded penta-peptide spectra (apo-subtracted spectra) summed together and directly compared to the apo-subtracted spectra of PrP(90-126) with 2 mole equivalents of Cu2+ ions present. The spectra used were for levels of Cu2+ ions just before saturation, with the molar ellipticity intensities of the spectra calculated by the concentration of Cu2+ ions present. The spectrum of Cu2+ ions with PrP(90-126) is very similar to that of PrP(107-111) and PrP(92-96) in combination. Both difference spectra show a negative CD band at 215-217 nm and a positive band at 198 nm. The wavelength position and intensities of CD bands for PrP(90-126) and the simulated summed spectra are quite similar; indeed, an even closer similarity would not be expected, as PrP(90-126) contains 36 amino acid residues while the simulated spectrum is derived from two five-residue peptides. The similarity between the spectra suggests that the Cu2+-induced changes observed for PrP(90-126) can largely be accounted for by local changes at the residues involved directly in Cu2+ coordination, to form a square-planner Cu2+ complex involving the His residues and the main-chain amide ligands, shown as configuration 1 in Figure 3.14a.




Figure 3.1 7: pH Dependence of Cu2+ Binding to PrP(90-126)
The UV-CD spectra of PrP(90-126) apo (red) and Cu2+ loaded (2 mole equivalents) PrP(90-126) (blue), at four different pH values; 5.8, 6.8, 7.8 and 8.8. Peptide concentration used is 45 μM at 25 ºC. The 3N1O complex for His111 and His96 dominates at pH 6.8 while at pH 8.8 the 4N complex dominates. The effect of Cu2+ ions on the secondary structure of PrP(90-126) is very similar between pH 6.8 and 8.8.  At pH 5.8 amide main-chain coordination does not take place, Cu2+ binding to His δN ligands only have a small effect on the secondary structure of PrP(90-126).

the appearance of the Vis-CD and EPR spectra previously published  ADDIN EN.CITE (; ; ; ; ; ; ). In contrast, pH dependent changes in secondary structure for the two complexes are very minor between pH 6.8 (3N1O complex) and pH 8.8 (4N complex).  In this instance a change in orientation of torsion angles of a single residue has little impact on the over-all secondary structure. Studies by a number of groups have shown that at lower pH (note main-chain amide coordination only dominates above pH 6) or sub-stochoimetric amounts of Cu2+ ions a greater proportion of Configuration 2 (Figure 3.14b) may be present  ADDIN EN.CITE (; ; ; ).   






Figure 3.1 8: Concentration Dependence of Cu2+ Binding to PrP(90-126)




It should be noted that spectra recorded over a 4 hour period for Cu2PrP(90-126) showed no change in appearance (data not shown), indicating that the Cu2+ induced changes in structure are rapid relative to the time taken to record spectra (~10 minutes). 
Cu2+ Binding to PrP(90-126), Analogues H96A and H111A. There remained a possibility that the increase in β-sheet like structure observed during Cu2+ ion additions, was due to the interaction between Cu2+ ions and both His residues simultaneously, as shown in Configuration 2 in Figure 3.14b. Consequently, two analogues of the amyloidogenic region were produced in which a single His residue was replaced with an alanine (Ala) residue, PrP(90-126)H96A and PrP(90-126)H111A. Figure 3.19a shows the UV-CD spectra of PrP(90-126)H96A with increasing additions of Cu2+ ions. Just as had been shown in Figure 3.15a, for the wild-type Cu2PrP(90-126), PrP(90-126)H96A adopts spectra characteristic of -sheet upon addition of Cu2+ ions, which can be clearly seen in the panel inset. The magnitude of the difference in Δε at 217 nm with Cu2+ binding, is comparable to the wild-type fragment, PrP(90-126). The formation of a band at 217 nm upon the addition of Cu2+ ions to the H96A analogue indicates that simultaneous binding to both His residues is not necessary for the -like appearance in the CD spectrum. This helps to confirm that the source of the change in secondary structure is simply the individual coordination of Cu2+ ions to the peptide (as shown in Configuration 1 in Figure3.14a). This is supported by the similarities in the apo-subtracted spectra for the PrP(107-111) and PrP(90-126)H96A peptides. 
Figure 3.19b shows the other analogue, PrP(90-126)H111A. Even in the absence of Cu2+ ions this peptide displays a -sheet-like conformation. A single mutation from His111 to Ala has a profound influence on the conformation of this natively unstructured region of PrPC. Increasing addition of Cu2+ ions causes a small conformational change chocolate 


Figure 3.1 9: Analogues of the Amyloidgenic Region, H96A and H111A
The far-UV-CD spectra of Cu2+ titrations at 0.15 mole equivalent additions up to 1.2 mole equivalents. a) PrP(90-126)H96A; b) PrP(90-126)H111A. The inset panels show the difference spectra for the Cu2+ titrations. PrP analogue with single His at residue 111 has a close similarity with Cu2+ additions to wild-type PrP(90-126). Peptide concentration of 20 μM was used at pH 7.4 and 25 ºC. (Data obtained by Mark Klewpatinond). 

from a -sheet-like structure to a more irregular unstructured conformation.
In summary, taken together, these studies suggest that the Cu2+-induced conformational changes in PrP(90-126) are largely due to local alterations in the  structure around the Cu2+ binding sites, due to direct Cu2+ coordination (Configuration 1 in Figure 3.14a) rather than a more widespread conformational rearrangement. The key evidence for this is as follows (i) the changes in secondary structure for PrP(90-126) can be replicated by the isolated penta-peptides (Figure 3.15d); (ii) stoichiometric binding of Cu2+ saturating at 2 mole equivalents is most consistent with Configuration 1; and (iii) PrP(90-126)H96A bares a striking resemblance to the PrP(90-126) CD spectra (Figure 3.19a) , ruling out Configuration 2.  Although, there are some intermolecular interactions observed for Cu2PrP(90-126), this is not the main source of the Cu2+-promoted CD band at 217 nm.
3.04.6 Biological Significance
It is generally accepted that the misfolding of PrPC to the scrapie isoform (PrPSc) involves a significant change in the conformation, with loss of some, if not all, α-helical content. Indeed, in vitro generation of PrP amyloids or infectious particles requires the addition of mild levels of denaturant  ADDIN EN.CITE (). Intriguingly, I show here that Cu2+ ions destabilise PrPC folding; this raises the possibility that Cu2+ ions might promote amyloid formation in vivo. The difference in free energy, ΔΔGU[D]50% 2.02 (±0.05) kJmol-1, between the prion protein loaded with a single mole equivalent of Cu2+ ions and apo-PrPC is quite appreciable and of comparable magnitude to the effect of certain mutations in the C-terminal domain, associated with familial prion disease () and also similar to the atypical destabilising effect of salts such as NaCl ().  A loss of copper ion homeostasis is a general feature of ageing and is linked to Prion disease (). I speculate that sporadic CJD may be associated with increased levels of Cu2+ ions, which can destabilise the fold of PrPC, therefore, may make the transition to PrPSc more thermodynamically favourable. It is notable that one form of familial Prion disease is linked to an increased ability to bind Cu2+ ions with additional octarepeats present (). Cu2+ ions can convert the PrPC into a protease-resistant species  ADDIN EN.CITE (; ), which is a feature of PrPSc. Furthermore, Cu2+ binding encodes features that correlate with various strains of Prion disease ().  Cu2+ binding lowers PrP solubility and promotes self-association, a factor of the mis-assembly process in Prion disease.  Furthermore, Cu2+ ions promote fibre formation for certain PrP alleles ().   Other in vitro experiments indicate that Cu2+ ions can inhibit amyloid formation, although, these studies were carried out at high protein concentrations, which may not reflect the behaviour in vivo.  Interestingly, the same study showed that, once amyloid fibres are formed, they are stabilised by Cu2+ ions  ADDIN EN.CITE ().  
It is now clear that Cu2+ additions of up to 6 mole equivalents to PrPC do not cause a switch in conformation to a more β-sheet-rich structure; only further Cu2+ additions (>6 mole equivalents) may cause some unfolding of the α-helices within PrPC.  I show that Cu2+ ion binding causes an ordering of the natively unfolded domain, these changes in main-chain conformation are particularly associated with Cu2+ coordination to the octarepeats. The change in structure of the N-terminal domain may well be the trigger for the endocytosis of PrP reported in the presence of Cu2+ ions, but this is not observed for the octarepeat-deleted PrPC (; ).











































Early research noted Met oxidation in PrPSc, although, this was dismissed as an artifact caused by isolation of PrPSc from brain homogenates (). However, recently Canello et al. have shown that a large fraction of the Met residues in brain PrPSc are present as methionine sulfoxides (MetOx), while, in PrPC these residues remained un-oxidised ().  The study went on to show that the MetOx formation was not an artefact of PrPSc isolation as previously believed ().  It is yet to be established whether the Met oxidation is a cause of the cascade of events that leads to PrPC misfolding and the formation of toxic oligomers and amyloid plaques.  The hypotheses on the role played by oxidative modification may include the destabilisation of PrPC, the promotion PrPSc formation or the inhibition of PrPSc clearance. Oxidative stress has been observed in early pre-clinical stages of mouse scrapie  ADDIN EN.CITE (), therefore, the oxidative process might represent a risk factor in sporadic Prion diseases (). Copper catalysed oxidation has been shown to provoke aggregation in the protein () and PK resistance (), both features of Prion diseases.  Using analogues of Met residues, the aggregation propensities of PrPC have been correlated with the degree of Met oxidation (). Indeed, metal catalysed oxidation can generate oligomeric species, 10-40 nm in diameter which corresponds to a complex of 25 to 100 PrPC molecules in size ().  Oligomeric and aggregated species may be favoured over fibre formation (). However, formation of amorphous aggregates, fibrils or oligomers is dependent on particular experimental conditions in vitro ().
The Met oxidation of PrPC in vitro has previously been characterised using mass spectrometry  ADDIN EN.CITE (; ; ; ).  In addition, the effect of Cu2+ catalysed oxidative damage has been reported for PrP  ADDIN EN.CITE (; ; ).  The Fentons and Haber-Weiss reactions of Cu2+ and Cu+ ions in the presence of a physiological reductant such as ascorbate are a  significant source of protein oxidation in vivo, generating highly reactive and damaging •OH radicals and other reactive oxygen species (ROS) such as H2O2  ADDIN EN.CITE (; ).  The Cu2+ and Cu+ redox reactions cause oxidation of both His residues to 2-oxo-His, and Met residues within PrPC. On the other hand, the oxidant H2O2 will readily cause the oxidation of Met residues to MetOx, while, the His residues remain unaffected  ADDIN EN.CITE (; ). The structure of MetOx and 2-oxo-His are shown in Figure 4.01.
The Cu2+ and Cu+ redox generated ROS can also mediate β-cleavage of the PrPC main-chain, typically at residue 112,  ADDIN EN.CITE (; ) and this can seed aggregation  ADDIN EN.CITE (). One study showed that Cu2+ and Cu+ ions can catalyse the cleavage and the dimerisation of PrPC (), interestingly, disulfide bound oligomers, created by a redox mechanism, exhibit seeding properties similar to PrPSc ().  
It is believed that proteins with solvent accessible Met residues can serve as a first defence against oxidative damage, scavenging ROS before they react with other cellular components (). The suggested function of PrPC might be to act as a sacrificial quencher of ROS generated by Cu2+ catalysed oxidation ().  The antioxidant role of PrPC is highlighted by the increased oxidative stress observed in prion protein knock-out mice  ADDIN EN.CITE (; ).


Figure 4.0 1: Oxidation of His and Met Residues
a) H2O2 oxidation of methionine produces methionine sulfoxide and methionine sulfone. b) Copper catalysed oxidation of histidine to 2-oxo-histidine.

	As previously discussed, PrPC has two distinct domains and most of the 9 Met residues (mouse sequence numbering) are found in the structured C-terminus; Met128, Met133, Met137, Met153, Met204, Met205 and Met212, while Met23 and Met37 is in the unstructured N-terminal domain. Absent in the mouse sequence, Met109 and Met112 in human PrP, are close to the Cu2+ binding residue His111 and His96 (). The Cu2+ ions bind to PrPC in a redox active form () involving His side-chain and main-chain amides in a tetragonal geometry (). This Cu2+ binding causes some conformational changes in the N-terminus, particularly associated with the octarepeats region of PrPC (), for more detail refer to chapter 3.
	Critical to understanding the molecular mechanisms involved in amyloid formation are the characteristics of the misfolding pathway and the role of folding intermediates in this process. In vitro, amyloid fibres of PrP can be generated at neutral pH in the presence of denaturants (). In addition, a soluble oligomeric form of PrP, with extended beta structure, has been identified the so called -oligomer, this form is favoured at low pH (~3.5-4.0) with high salt content  ADDIN EN.CITE (; ; ; ; ). Initial studies suggested that at low pH, PrPC would not generate amyloid fibres (), however it is now clear these low pH condition are also capable of producing fibres  ADDIN EN.CITE (; ). Characterisation of this species by NMR suggested the N-terminal residues (23-118) are unstructured and highly flexible while the C-terminal residues formed a molten-globule or oligomeric species (). Subsequent studies suggest a transition from a molten-globule, monomeric, -helical species at pH 4.1, to an oligomeric species with β-strand content at pH 3.5 (; ). This pH 4 folding intermediate is of particular interest because it is on the pathway to fibre formation under physiologically attainable conditions; non-physiological denaturants such as urea not required (). Similarly, the influence of oxidation of side-chains from PrPC on the folding and stability has physiological relevance, here we show oxidised PrP misfolding has striking similarities to the folding of PrP at pH 4-3.5. This suggests that PrPC might share aspects of a misfolding pathway, even under very different conditions.
4.02.1 Aims





4.03 Materials and Methods 
Techniques described here are specific to chapter 4, for a detailed description of the techniques and protocols in particular urea denaturation studies, FT-IR, far-UV- and Vis-CD measurements used throughout this chapter refer to chapter 2.
4.03.1 Oxidation Treatment 
PrP samples were oxidised by incubation with H2O2 or a mixture of H2O2 and Cu2+ ions. 
The treatments were performed at two different sets of conditions. One set was under a concentration of PrP suitable for CD measurements and the other set of conditions made more suitable for NMR structural studies. In particular, low levels of the paramagnetic Cu2+ ions are used for the NMR studies. The details of these oxidising conditions are summarised in Table 4.01 below. Once prepared, the samples are then incubated at      37 ºC for 10 to 15 hours. When I am referring to the oxidising conditions as ‘harsh’ or ‘mild’ I am taking about the H2O2 to PrP ratio, please refer to Table 4.01, below, for more information on all the oxidising conditions I used. 
Table 4.0 1: Oxidation Conditions
	Harsh Oxidising ‘CD’ Condition	Mild Oxidising ‘NMR’ Condition
Cu2+ and H2O2	4 μM PrP(23-231)0.4 μM Cu2+ ions10 mM H2O2	130 μM PrP(23-231)13 μM Cu2+ ions10 mM H2O2
H2O2 alone	4 μM PrP(23-231)10 mM H2O2(50 μM EDTA)	130 μM PrP(23-231)10 mM H2O2(50 μM EDTA)
(Under the NMR condition; samples were made using the concentrations shown in the table but before running the urea denaturation the samples were diluted to 0.1 mg/ml of PrPC and the samples were incubated at 37 ºC but the denaturation studies were carried out at 25 ºC).
4.03.2 Nuclear Magnetic Resonance (NMR) Spectroscopy 
Main-chain amide resonance assignments have been previously reported by O’Sullivan et al. for mouse PrPC (). Assignments of H2O2 oxidised PrP(113-231) were made using un-oxidised assignments as the starting point. All NMR spectra were acquired at 37 ºC on a Bruker Avance spectrometer operating at 600 MHz for 1H nuclei using a 5 mm inverse detection triple-resonance z-gradient probe.
Typically, 1D 1H NMR spectra were obtained with 128 transients, consisting of 64 K complex points over a sweep width of 8,389 Hz.  Data was processed using an exponential Fourier transform window, with a 2.0 Hz line broadening. Residual water was suppressed using either pre-saturation, excitation sculpting with gradients solvent suppression, method () or the Watergate method ().  
Phase sensitive 2D 1H-15N HSQC NMR spectra were acquired using echo-antiecho gradient selection. The 1H acquisition parameters were 0.122 seconds acquisition time, 1 second fixed delay and 2048 complex (t2) points while 256 complex points were collected for the 15N dimension.  Thirty two transients were recorded for each spin lattice relaxation time (t1) interval.  The 1H and 15N dimensions possessed spectral widths of 14 ppm and 25 ppm respectively.  The 15N dimension was zero filled to 256 data points before squared cosine apodisation and Fourier transformation.  
The extent of the chemical shift perturbations (CSP) in the 1H and 15N NMR chemical shifts of each amide resonance were presented as a standard weighted sum according to equation 1 (eq 1)  ADDIN EN.CITE ().
						(eq 1)
 CSP were mapped onto the structure of mouse PrPC (PDB reference 2L1H)  ADDIN EN.CITE (; ).
4.03.3 Urea Denaturation
PrP(23-231) was incubated at either 4.3 μM or 130 μM concentration  to mimic the NMR and CD conditions used (see Table 4.01) in 10 mM sodium acetate (NaOAc) buffer at pH 5.5. Incubations under oxidative conditions (H2O2 alone or H2O2 and Cu2+) were for 10-15 hours at 37 ºC. Samples were then diluted to 4.33 μM PrP(23-231) for the urea denaturations. Typically, titrations were performed by combining stock solutions of PrPC in either 10 M urea or just in buffer; to avoid any dilution of protein concentration with the addition of urea. CD measurements for the urea unfolding studies were recorded at 225 nm along with a measurement at 260 nm to account for any baseline offset. All urea denaturation experiments were carried out at 25 ˚C (after incubation under the oxidising conditions).
4.03.4 Gel Filtration Chromatography 
An aqueous buffer of 10 mM NaOAc with 500 mM NaCl, pH 5.5, was used at a flow rate of 0.5 ml min-1. Typically, the sample injection was 0.5 ml of 0.1 mg/ml PrP all carried out at 4 ºC.
4.03.5 Single-Cell Fluorescence
















4.04.1 Core Hydrophobic Packing within PrPC is Perturbed by Oxidation of Methionine 
As oxidative stress is observed in the early pre-clinical stage of scrapie infection  ADDIN EN.CITE () and a high proportion of Met residues within scrapie isolates are oxidised (), I was interested in the effect of oxidation on the structure and stability of PrPC. The effect of oxidation over time was determined by monitoring changes in the main-chain amide NMR chemical shifts of PrPC by recording 2D 1H-15N HSQC NMR spectra. These amide chemical shift perturbations (CSP) can be used to monitor changes in the structure on a per-residue basis. 
I used H2O2 to oxidise PrPC, the effects of H2O2 oxidation on both PrP(113-231) and PrP(23-231) are very similar, shown in Figure 4.02 and Figure 4.03. Under these oxidising conditions (10 mM H2O2 with no Cu2+ ions) the changes in the spectra are largely complete by 9 hours; as there is little difference between spectra recorded at 9 hours and that recorded at 20 hours. Separate sets of signals are observed for the oxidised and un-oxidised PrPC.  This would be expected as oxidised PrP is a covalently altered specie; rapid exchange between these species does not take place. For those residues that are perturbed by oxidation the intensity of the un-oxidised signals are completely lost in less than 9 hours, while, the new set of signals belonging to the oxidised PrP have a comparable intensity to the un-oxidised signals. Furthermore, there is no significant increase in the 1D 1H NMR line-width between 0 and 20 hours spectra upon incubation with H2O2 and the intensities also remain similar suggesting after 9 hours of oxidation there is a single oxidised form of PrPC which is predominantly monomeric.  This is in agreement with the gel filtration chromatogram that suggests chocolate   

Figure 4.0 2: Methionine Oxidation of PrP(113-231)




Figure 4.0 3: The 2D 1H-15N HSQC NMR Spectra of H2O2 Oxidised PrP(23-231)
Un-oxidised PrP(23-231) spectra (black), oxidised PrP(23-231) for 3 (red) and 9 hours (blue) of incubation at 37 ºC. PrP(23-231) (130 μM) oxidised with 10 mM H2O2 in 10 mM NaOAc at pH 5.5. The residues perturbed by H2O2 oxidation are the same as those observed from PrP(113-231), shown in Figure 4.02.


PrPC oxidised by H2O2 alone remains monomeric, seen in Figure 4.04.
From a total of 98 resolved amide residues, in PrP(113-231), most are only mildly perturbed in terms of the amide main-chain 1H-15N chemical shifts (CSP values), Figure 4.05b. Specifically, 69 amino acids display changes in their chemical shift by less than 0.04 ppm. This indicates that the basic fold of PrPC is unaffected under these conditions. However, there are 29 amide main-chain resonance signals that do have significant changes in their 1H and 15N shifts (>0.04 ppm).  As might be expected these include Met residues (specifically Met128, Met133, Met137, Met205 and Met212), although, Met 153 and Met 204 are not significantly perturbed (<0.02 ppm shifts).  Perturbations are not restricted to these residues, indeed, the most perturbed resonances are not from the Met main-chain amides. The amide resonances that show the most significantly perturbations are highlighted on the structure of PrPC in Figure 4.05a.  
Perturbed residues are concentrated on one face of helix-C, (residues V209, M212 and Q216) together with residues M133 and V160 which form a part of the extended structure either side of a short stretch of anti-parallel β-sheet structures. These side-chains are highlighted in the structure of PrPC, Figure 4.05a. These hydrophobic residues (V209, M212, V160 and M133) pack together and stabilised the structure. A second group of residues that have significant chemical shift perturbations, these include the hydrophobic residues I138, F140 and residue E145 which are situated in the extended structure (also shown in Figure 4.05a). These residues form close contacts with each other and two Met residues; M137 and M205. In addition, there are a number of residues in helix-A that have some chemical shift perturbations, in contrast amide chemical shifts in helix-B remain mostly unperturbed. 




Figure 4.0 4: Gel Filtration Chromatogram of Oxidised PrP(23-231) by H2O2





Figure 4.0 5: Residues Most Perturbed by Oxidation of PrPC
a) Structure of PrPC with Met and His side-chains shown.  The residues are color coded according to chemical shift perturbation (CSP).  Dark blue, little change (<0.04 ppm CSP); light blue (0.04 to 0.08 ppm); purple (0.08 to 0.12 ppm), pink to dark red (>0.12 ppm).  b) Plot of chemical shift perturbations per residue, strongly perturbed amide resonances are highlighted along with a diagrammatic representation of the structural regions of PrPC showing the three α-helices (residues 144-156, 172-193 and 200-227) C. Nadal).
side-chain hydrophobicity (). As a consequence, there are rearrangements of the hydrophobic packing upon oxidation of the Met side-chain. It is clear from Figure 4.05a residues that are in close contact with the Met side-chains (M133, M137, M205 and M212) have their conformation perturbed as a consequence of oxidation as this in-turn perturbs the environment of the main-chain amides. The oxidation of the εS at the end of the Met side-chain will not necessarily result in a significant perturbation the same Met amide resonance, as in the case of the partially solvent exposed M153.  The oxidation of M212 in the hydrophobic core of PrPC appears to be a key Met residue in perturbing the structure.  The 2D 1H-15N HSQC NMR data suggests that although M212 is substantially buried in the structure, H2O2 will readily oxidise this residue.
I have carried out the same treatment on full-length PrP and the same oxidation occurs, as the same set of new resonances for the oxidation of PrPC appear in the 2D 1H-15N HSQC NMR spectrum, as shown in Figure 4.03. This indicates that H2O2 oxidation affects the structured domain of PrP similarly in full-length PrPC, residues 113-231, the unstructured N-terminal domain does not significantly influence H2O2 induced oxidation in the structured domain.   
4.04.2 Methionine Oxidation Destabilises the Native Fold of PrPC
It is clear from the 2D 1H- 15N HSQC NMR data presented in Figure 4.02 and Figure 4.03 that the hydrophobic core of PrPC is perturbed by Met oxidation but the fold of PrPC remains intact. I wanted to determine whether oxidation of PrPC has destabilised this native fold. Urea denaturation folding curves were generated for PrP(23-231) under various oxidising conditions and compared to un-oxidised  PrP(23-231). PrPC exhibits a rapid and essentially a two-step unfolding. The CD signal at 225 nm, was used to monitor PrPC folding over a range of urea concentrations, shown in Figure 4.06. The urea concentration at the mid-point of unfolding, [D]50%, of PrP(23-231) is 5.2 (± 0.1) M at pH 5.5. 
PrP(23-231) was oxidised by incubation with H2O2 under two sets of conditions that mimic the oxidative condition used in the NMR experiments and CD experiments described in section 4.03.1, summarised in Table 4.01. PrP samples were incubated for 8 hours under the H2O2 oxidising conditions prior to the urea unfolding studies. Under both sets of conditions, the oxidation of the prion protein caused significant destabilising of the native fold of PrPC. Figure 4.06 shows unfolding under the same oxidising condition used in the NMR experiments. The [D]50% drops from 5.2 ± 0.1 M urea in un-oxidised PrPC to 4.2 ±0.1 M urea for H2O2 oxidised Prion protein. The oxidation generated under the harsher, so called CD conditions, causes significantly more destabilisation of the native fold of PrPC, also shown in Figure 4.06. The oxidised forms of PrPC are considerably less stable. 
The thermodynamic parameters are summarised in Table 4.02.  The difference in the Free energy of unfolding at the mid-point of the folding transition, ΔΔGu(50%),  between oxidised and un-oxidised is 2.7 ± 0.4 kJmol-1 when the sample undergoes oxidation by H2O2 using the condition used to obtain the NMR data.  Higher ratios of H2O2 to PrPC cause even more destabilisation and an increases in the difference in ΔΔGu(50%) of 8.9 ± 0.6 kJmol-1 between the un-oxidised and oxidised PrPC.
The transition between folded and unfolded is less defined for the mild oxidising conditions, Figure 4.06. This is reflected in the folding cooperativity value (m) which is 3.1 ± 0.1 kJmol-1M-1 for native PrPC and 2.3 ± 0.1 kJmol-1M-1 for the H2O2 oxidised protein.  This might reflect a mixture of oxidised species for the mildly oxidising condition. At higher ratios of H2O2 to PrPC the cooperativity of unfolding is quite chocolate 

Figure 4.0 6: Urea Unfolding of H2O2 Oxidised PrP(23-231)
Far-UV-CD spectra showing a chemical denaturation (using urea) data at 225 nm of un-oxidised PrP(23-231) (triangles), H2O2 oxidised PrP(23-231) under mild NMR condition (circles), repeat measurement (crosses) and H2O2 oxidised PrP(23-231) under hasher CD condition (squares). All carried out in 10 mM NaOAc at pH 5.5 and 25 ºC with a protein concentration of 4.3 μM.

Table 4.0 2: Urea Unfolding Stabilities
PrPC	[D]50%(M)	ΔGuH²O(kJ/mol)	m(kJ/mol/M)	ΔΔGuH²O (kJ/mol)	ΔΔGu[D]50%(kJ/mol)
Un-oxidised 	5.2 ± 0.1	16.7 ± 0.4	3.1 ± 0.1	-	-
H2O2 oxidised NMR condition	4.3 ± 0.1	9.4 ± 0.4	2.3 ± 0.1	7.3 ± 0.6	2.7 ± 0.4
H2O2 oxidised CD condition	2.2 ± 0.1	7.8 ± 0.4	3.4 ± 0.2	8.9 ± 0.6	8.9 ± 0.4
The denaturation was carried out at pH 5.5, 24 ºC.  Standard errors are shown. 
, where the used <m> value: 3.1 ± 0.3 kJmol-1M-1.


similar   for   un-oxidised   and   oxidised   PrP;  3.1  ±  0.1  and  3.4  ±  0.2  kJmol-1M-1, respectively. It is clear that the oxidation of the Met residues significantly destabilises the native fold, the extent of destabilisation increases with Cu2+ catalysed oxidation. 
As with un-oxidised PrPC, I have confirmed that the urea unfolding of oxidised prion protein is also reversible as shown in Figure 4.07.  We also investigated the thermal unfolding of oxidised compared to un-oxidised PrP.  Again oxidation destabilises the PrP fold, however, thermal unfolding is not reversible and this data has not been analysed any further.
4.04.3 Cu2+ Catalysed Oxidation Generates a Monomeric Molten-Globule PrP Conformation Rich in Beta-Sheet




Figure 4.0 7: Reversible Unfolding of H2O2 Oxidised PrP(23-231)






Figure 4.0 8: 2D 1H-15N HSQC NMR Spectra of PrP(23-231) with 0.1 Mole Equivalent Cu2+




Figure 4.0 9:  2D 1H-15N HSQC NMR Spectra of Cu2+ Catalysed Oxidation of PrP(23-231)
Un-oxidised PrP(23-231) (red), Cu2+catalysed oxidation of PrP(23-231) after 4 hours of incubation (green) and 16 hours of incubation (blue). PrP(23-231) (3 mg/ml) oxidised with 10 mM H2O2 and 10 % Cu2+ ions in 10 mM NaOAc at pH 5.5. After 4 hours some resonances from helix-C retain the signal and chemical shift values while many other signal from the structured domain lose their signal intensity due exchange broadening of a molten-globule fold.
the topology of the PrPC fold is to some degree retained during Cu2+ catalysed oxidation.  Many of the 2D 1H-15N HSQC NMR signals reduce in intensity over time.  However, after 16 hours approximately a third (~70 out of ~200) of the amide signals are still retained, these signals have little chemical shift dispersion and are assigned to the unfolded N-terminals domain of PrPC, residues 23-118.
The loss of NMR signals can be attributed to considerable line-broadening of signals.  The increase in line-width can be due to the formation of a high molecular weight oligomeric species; alternatively, the formation of a molten-globule fold can cause significant line-broadening of NMR signals due to slow (milli-second) conformational exchange dynamics of the main-chain. The paramagnetic broadening by the Cu2+ ion has been ruled out, see Figure 4.08. 





Figure 4.1 0: A Gel Filtration Chromatogram of Cu2+ Oxidisation of PrP(23-231)




oligomer. After 9 hours of oxidation the intensity of the elution bands indicates that most of the PrPC present is still detected eluting from the column as a monomer. Even after 20 hours of incubation the main band eluting from the column is indicative of a monomeric species. It is only at 27 hours of incubation that fragmentation of PrP with an elution band at approximately 13 kDa is observed.  It is well documented that Cu2+ ions with H2O2 can cause peptide cleavage at reside 112 of PrPC to generate a 13 and 10 kDa fragments  ADDIN EN.CITE (; ).
The gel filtration chromatography suggests that the broadening in the 2D 1H-15N HSQC NMR spectra (after 9 hours) is due to the formation of a monomeric molten-globule rather than oligomerisation of PrPC.  This is supported by the NMR data, as a number of peaks from the unstructured portion of PrPC remain intense. Furthermore, eight residues from helix-C also retain their intensity and native chemical shift values, indicating that a large oligomeric species (with the associated increase in line-width) has not been formed. 
Further support for the generation of a less compact, molten-globule, fold is derived from the far-UV-CD spectra of PrP(23-231) oxidised under the same mild Cu2+ catalysed condition, the so called NMR condition. It is clear from the far-UV-CD spectra, shown in Figure 4.11, that there is almost no change in the secondary structure after 4 hours of oxidation even though the 2D 1H-15N HSQC spectra (Figure 4.09) exhibits profound changes in appearance. The lack of change in secondary structure, even after 16 hours of incubation would be expected if a molten-globule was formed in which the basic helical topology remained unchanged but in a less compact form.
Next, I studied the thermodynamic folding stability of PrPC after undergoing Cu2+ catalysed oxidation, by monitoring unfolding  in the presence of Urea, Figure 4.12.  

Figure 4.1 1: Structural Transitions Monitored by Far-UV-CD of Oxidised PrPC and its Fragments
a) PrP(23-231) (130 mM) incubated with H2O2 (10 mM) and Cu2+ (0.1 mole equivalents) b) PrP(23-231) (130 mM) incubated with H2O2 (10 mM) only c) PrP(113-231) incubated with 10 mM H2O2 and 0.1 mole equivalents of Cu2+ ions at pH 5.5 over 20 hours at 37 °C, 2 hour time intervals are shown. Inset, the change in molar ellipticity, at 225 nm with time. d) PrP(113-231) incubated with 10 mM H2O2 and 0.05 mole equivalents EDTA at pH 5.5 over 20 hours at 37 °C, with 0 hour and 20 hours spectra shown only. e) PrP(23-231) incubated with 10 mM H2O2 and 0.1 mole equivalents of Cu2+ ions at pH 5.5 over 20 hours at 37 °C, 2 hour time intervals are shown. Inset, the change in molar ellipticity, at 225 nm with time. f) PrP(23-231) incubated with 10 mM H2O2 and 0.05 mole equivalents EDTA at pH 5.5 over 20 hours at 37 °C, with 0 and 22 hours spectra shown only.  Spectra after 20 hours incubation are depicted as dashed lines in all panels. (Parts c to f are data obtained by Rebecca C. Nadal). 

Figure 4.1 2: Urea Denaturation of Cu2+ Catalysed PrP(23-231) Oxidation
Far-UV-CD spectra at 225 nm of un-oxidised PrP(23-231) (triangles), PrP(23-231) with 0.1 mole equivalent Cu2+ (filled triangles), Cu2+ catalysed oxidised PrP(23-231) under mild NMR condition (circles) and Cu2+ catalysed oxidised PrP(23-231) under hash CD condition (squares) with increasing [urea]. All carried with a protein concentration of 4.3 μM using 10 mM NaOAc at pH 5.5 and 25 ºC.

Table 4.0 3: Urea Unfolding Stabilities
PrPC	[D]50%(M)	ΔGuH²O(kJ/mol)	m(kJ/mol/M)	ΔΔGuH²O (kJ/mol)	ΔΔGu[D]50%(kJ/mol)
Un-oxidised 	5.2 ± 0.1	16.7 ± 0.4	3.1 ± 0.1	-	-
Un-oxidised 0.1 mole equiv Cu2+	5.4 ± 0.1	17.1 ±1.5	3.1 ± 0.3	-	-
H2O2 and Cu2+ oxidised NMR condition	4.2 ± 0.4	6.9 ± 0.5	1.8 ± 0.1	9.8 ± 0.6	3.0 ± 0.6
H2O2 and Cu2+ oxidised CD condition	~ 0* 	~ 0*	-	-	-

The denaturation was carried out at pH 5.5, 25 ºC.  Standard errors are shown. 
, where the used <m> value: 3.1 ± 0.3 kJmol-1M-1. 
From the urea unfolding measurements, it is clear that PrPC is destabilised considerably more in the presence of Cu2+ ions than oxidation of proteins with H2O2 alone. Relatively, mild Cu2+ catalysed oxidation (which generates an α-helical molten-globule) causes destabilisation of PrPC as indicated by a reduction in the urea induced mid-point of unfolding from 5.2 ± 0.1 to 4.2 ± 0.4 M urea.  This equates to a difference in ΔG50% of 3.0 ± 0.6 kJmol-1, see Table 4.03. 
4.04.4 Further Cu2+ Catalysed Oxidation Promotes Extended Beta-Strand like Conformations in PrPC with Little Stability
It is clear that under the oxidising conditions used for the NMR experiments, described earlier, there are quite profound perturbations in the 2D 1H-15N HSQC NMR spectra and reduced stability of the native fold. However, there is very little change in total secondary structure, as indicated by CD spectra for both the H2O2 oxidised and Cu2+ catalysed oxidation, shown in Figure 4.11a and b. 
Next, I wanted to probe the structure of PrP under harsher oxidising conditions using FT-IR and far-UV-CD. I incubated PrPC in the presence of oxidising H2O2 or a mixture of H2O2 and Cu2+ ions, and recorded a far-UV-CD spectrum every 2 hours. Figure 4.11 shows the effect of oxidation under these two different conditions on bothe the C-terminal structured domain, PrP(113-231) (Figure 4.11c and d) and full-length PrP(23-231) (Figure 4.11e and f). Over 10 hours of incubation in the presence of Cu2+ and H2O2 (harsher oxidising condition) will cause the loss of the α-helical signal, as indicated by a loss in intensity of bands at 222, 208 and 190 nm and an increase in extended β-strand structure, as indicated by the appearance of a minimum at 217 nm. The inserts, within Figure 4.11c and e, show the change in the helical CD signal at 225 nm over time. Most of the changes occur in the first 10 hours of incubation, after this there is little change in the spectra. 
Under stronger oxidising conditions (Cu2+ with H2O2 under CD conditions refer to Table 4.01) there is a large reduction in the CD signal at 225 nm even in the absence of urea, indeed, the CD spectra are more indicative of β-sheet. It is clear from the reduction in ∆ε at 225 nm, by more than half, and also the appearance of the unfolding curve, Figure 4.12, that the Cu2+ catalysed oxidation under the harsher conditions produces an extended β-stand form of the protein which has very little stability. Addition of very small amounts of urea (0.1 M) to PrP oxidised under these conditions immediately causes further loss in the secondary structure, suggesting the apparent structure formed does not poses a cooperative fold. For this reason a [D]50% value is not determined.
The far-UV-CD spectra many not readily distinguish between regular stable β-sheets and extended main-chain conformation that may not have formed a regular hydrogen-bonding network. The urea unfolding measurement indicates that the extended β-strand like conformation indicated by CD is too unstable to be from highly ordered β-sheets, typically found in amyloids.
Incubation with H2O2 alone (under the harsher CD condition) causes a loss of α-helical signal, while less β-sheet-like CD signal to be generated, as the negative band at 217 nm is less apparent, Figure 4.11d and f. Urea unfolding measurements under this condition shows a substantial reduction in stability, but reveal that the cooperative fold is still maintained, as shown in Figure 4.06. To confirm the changes in the CD where due to oxidation of PrP, un-oxidised PrPC shows no change in the far-UV-CD spectra when recorded over a 20 hour period. Similarly, addition of small sub-stoichiometric amounts of Cu2+ ions (0.1 mole equivalent) to PrPC (in the absence of H2O2), causes no change in the far-UV-CD spectrum, recorded over a 20 hour period, Figure 4.13. Low levels of Cu2+ alone have no effect on the structure of PrPC. For both experiments the chocolate

Figure 4.1 3: The Effects of 0.1 Mole Equivalents of Cu2+ Ions on the Secondary Structure of PrP(23-231)
a) Far-UV-CD spectra of PrPC with 0.1 mole equivalents Cu2+ added (no H2O2). Spectra was recorded every 2 hrs up to 20 hours. b) FT-IR spectra of PrPC with 0.1 mole equivalents Cu2+ added (no H2O2) no change in α-helical amide-I band was observed. 
concentration of PrP(23-231) used was 8 μM at pH 7.4. Far-UV-CD spectra of PrPC oxidised under these milder and only in the presence of H2O2 show only minor changes in the appearance of the CD spectra Figure 4.14. 
The possibility that the reduction of the α-helical signal in the CD spectrum was simply due to some precipitation of PrPC and consequently a loss of signal was considered. However, UV absorption spectra recorded after 20 hours indicates some light scattering due to aggregation but only a relatively small reduction in the absorption band at 280 nm. ATR-FT-IR has the advantage that interpretations of secondary structure proportions are not so influenced by a loss of signal due to precipitation. The ATR-FT-IR data, shown in Figure 4.15 confirms that there is a gain in the β-sheet content for PrP(23-231) incubated in the presence of Cu2+ ions and H2O2 and also to a lesser extent by H2O2 oxidation alone. In particular, Figure 4.15a, shows the FT-IR spectra of Cu2+ catalysed oxidation of PrP(23-231) compared to un-oxidised PrPC. The frequency of the amide-I band is diagnostic of secondary structure. The band at 1650 cm-1 is typical of a protein with a high α-helical content and some irregular structure as would be expected for PrP(23-231). After incubation with Cu2+ ions and H2O2 for 20 hours a significant shoulder on the amide-I band appears at 1630 cm-1 this is characteristic of β-sheet formation. Figure 4.15b shows the effect of oxidation of PrP(23-231) by H2O2 only.  After oxidation a slight shoulder appears at ~ 1630 cm-1 indicative of β-sheet. PrPC was also incubated with Cu2+ ions in the absence of H2O2 to confirm the effects were not due to Cu2+ ions binding to the protein alone, shown in Figure 4.13b. It appears that oxidation of PrPC under these hasher conditions will causes a loss in -helical content and an increase in extended -strand character, particularly for the Cu2+ catalysed oxidation. 


Figure 4.1 4: Far-UV-CD Spectra of Oxidised PrPC under NMR Conditions






Figure 4.1 5: FT-IR of PrPC Oxidation





4.04.5 A Foot Note on PrPC Oxidation Protocols 
The H2O2 is highly oxidising but will not generate hydroxyl radicals. The •OH radicals can be generated by redox cycling Cu2+ ions by addition of a reducing agent, such as ascorbate, under aerobic conditions. A mixture of H2O2 with Cu2+ ions will also undergo Fenton and Habar-Weiss reactions and generate the highly reactive •OH radical (). I avoided the use of reductants such as ascorbate that will absorb light in the far-UV region and therefore may interfere with CD measurements. The ability of this reaction mix, under these conditions (Table 4.01), to generate appreciable •OH radicals was confirmed by a 3-Coumarin carboxylic acid assay (3-CCA), assay results shown in Figure 4.16 (). The product, 7-OH-CCA, fluoresces at 450 nm with an excitation maximum at 388 nm.  





Figure 4.1 6: Detection of •OH Radicals by 3-CCA Assay






Figure 4.1 7: 1D 1H NMR Spectra of PrP Incubated in H2O2




Oxidative stress is a feature of a number of protein misfolding diseases.  For example, oxidised Met residues have been found at high levels in amyloid-β plaques of patients suffering from Alzheimer’s disease ().  Metal associated oxidation of α-synuclin, of Parkinson’s disease, promotes fibril formation () and also has implications for Amyotrophic Lateral Sclerosis  ADDIN EN.CITE (). Oxidative stress is essential for the pathogenesis of Prion disease  ADDIN EN.CITE (; ; ; ; ; ; ; ; ; ; ), notably stress markers are observed in the early, pre-clinical, stages of scrapie infection  ADDIN EN.CITE (). Significantly, a large fraction of PrPSc isolates contain oxidised Met residues ().  In vivo, it is not clear if the significant oxidation of the Met residues within PrPC causes the cascade of events leading to prion protein misfolding, miss-assembly and disease. Alternatively, oxidation of PrPC could be a consequence of prion protein accumulation.  
The structural studies shown here characterise the effect of PrPC oxidation on a per residue basis. I have shown that the oxidation of the Met residues to MetOx substantially destabilises the secondary structure of PrPC, by as much as 9 kJmol-1. In particular, the data shows the hydrophobic residues; V209, V160 and Y156 that pack against Met212 and Met205 are the key residues perturbed upon Met oxidation. Thermodynamically, the misfolding of PrPC to PrPSc might be more favoured by destabilising the cellular form. In support of this, Met212 and Met205 in helix-C have been highlighted as key residues that are oxidised preceding the formation of a PK resistant PrPSc (). In addition, molecular-dynamic simulations have suggested  the oxidation of M212 (M213 in the human sequence) destabilises PrPC (). 
It is well established that Cu2+ ions bind to PrP in vivo (). PrPC is concentrated at the synapse () where fluxes of Cu2+ are released during neuronal depolarization and may reach 15-250 micromolar levels  ADDIN EN.CITE (; ; ). Cu2+ ions bind to PrPC in a redox active form that will readily generate hydroxyl radicals, H2O2 and other ROS in the presence of a reducing agent. Over time small amounts of Cu2+ ions will catalytically generate appreciable levels of ROS.  Like H2O2, Cu2+ catalysed oxidation will oxidise Met residues to MetOx but it will also oxidise PrP more widely, in particular, the His side-chains become oxidised to form 2-oxo-His  ADDIN EN.CITE (; ; ; ; ; ). It is clear that binding of even small amounts of Cu2+ ions to PrPC (0.1 mole equivalents) in the presence of physiological levels of reducing agent will profoundly destabilise the fold of PrPC giving rise to a molten-globule structure in the C-terminal half of the protein.  
Interestingly, the molten-globule species generated by Cu2+ catalysed oxidation, shown here, has some very close parallels with the misfolded form of PrP generated under acid conditions, pH 3.5-4.1 (). This form of PrP, referred to as the low pH intermediate, also forms a molten-globule in the C-terminal domain (). There is a transition from a molten-globule, monomeric, α-helical rich species at pH 4.1 to an oligomeric species with β-strand like content at pH 3.5 (; ). Recent studies have shown this low pH from of PrP will generate amyloid fibres  ADDIN EN.CITE (; ). A strikingly similar behaviour is observed for Cu2+ catalysed oxidised forms of PrP.  Milder oxidising conditions generate a monomeric, molten-globule form of PrP with native levels of α-helix. Further oxidation generates β-strand like content which has been shown to be oligomeric; 25- 100 PrPC molecules in size (). Our urea unfolding studies suggest this extended conformation has not formed a stable cooperative fold.  It appears that although the conditions under which PrPC is destabilised (oxidation or low pH) are very different, the misfolding pathway is shared.  These observations add credence to the possibility that fibre formation under a variety of conditions will share a generic folding pathway.  











The Influence of the Prion 














In this introduction I give a brief outline of the main molecular features associated with Alzheimer’s disease (AD) and the amyloid cascade hypothesis. In the latter half of this section I highlight what is currently known about the interaction between the amyloid-β peptide (Aβ) and the prion protein (PrPC).
5.02.1 Alzheimer’s Disease
Alzheimer’s disease is thought to affect 27 million people worldwide; this number is predicted to quadruple in the next 40 years (). This disease has strong correlation with age, where people aged between 60-65 years correspond to 1% of the cases, however, the 85+ age group contributes 24 to 33 % of the cases (). Nevertheless, AD has also been linked to other factors such as diet, lifestyle, mental and physical activity. 
	This neurodegenerative disease has without a doubt existed for over millennia, but was first characterised by Alois Alzheimer in 1907. While examining the cerebral cortex, following an autopsy, he noticed the presence of senile plaque deposits and neurofibrillary tangles (). The plaques and neurofibrillary tangles are most prominent in the medial temporal lobe structures and cortical areas of the brain; another observable feature is the degeneration of the neurons and synapses (). Figure 5.01 highlights the difference observed between the brain of a healthy person and the brain of an AD patient. Chocolate 
5.02.2 Amyloid Precursor Protein Processing





Figure 5.0 1: Brain with Alzheimer's Disease





neurofibrillary tangles, these are the product of hyperphosphorylated tau proteins (). In humans, Aβ is derived from the amyloid precursor protein (APP), which is encoded on chromosome 21 (). Like PrPC, Aβ is produced universally throughout the body, but concentrated in the brain  ADDIN EN.CITE (), and undergoes a series of post-translational modifications. These modifications follow one of two pathways, one known as the amyloidogenic pathway, which leads to the formation of Aβ and eventually to disease, the other is referred to as the non-amyloidogenic pathway. The amyloidogenic pathway is initiated by β-secretase mediated cleavage (BACE) of APP (), producing a βAPP and the C-terminal C99 membrane bound fragment. The non-amyloidogenic pathway initially involves α-secretase ()  which  cleaves  APP  in  the  middle  of  the Aβ  sequence, to  form α-APP and a C-terminal fragment. In both processes, the following step involves the cleavage by γ-secretase, within the trans-membrane. In the amyloidogenic pathway this produces the amyloid intracellular domain (ACID) and Aβ, when cleaved at residue 712 it produces Aβ40, but if cleaves at 714 it produces Aβ42. However, in the non-amyloidogenic pathway Aβ is not produced, but instead the shorter p3 peptide is generated. The sites of cleavage are summarised in Figure 5.02a.
5.02.3 The Genetics of Alzheimer’s Disease 





Figure 5.0 2: Amyloid-Beta Peptide





For many years, it was hard to characterise the protein responsible for the amyloid deposits found in the meningocerebral blood vessels and neuritic plaques, due to the insoluble nature of the senile plaques. It was not until the mid-1980’s that Masters et al. and Glenner et al. found that these deposits contained insoluble amyloid fibrils approximately 8-10 nm in diameter, largely comprising of a small 42 residue peptide, Aβ,  ADDIN EN.CITE (; ).
	In vivo, Aβ can vary in length, from 39-43 residues, but the most biologically relevant are Aβ40, residues from 1 to 40, and Aβ42, residues from 1 to 42. The first 15 amino acid residues are hydrophilic, and can be seen in Figure 5.02a. The following five residues make up the hydrophobic cluster, together with residues 30-42. The amino acid residue at position 43, found in the rare form of the peptide, Aβ43, is a threonine (Thr). This residue is an uncharged residue with low aggregation ability, this fact along with the low abundance of Aβ43 makes this peptide less biologically relevant. The Aβ40 peptide was found to be more soluble, more abundantly secreted and responsible for 90 % of the Aβ present ().  While, Aβ42 is less abundant, but it is considered to be more amyloidogenic and shows a significantly higher rate of fibril formation (). Figure 5.02b summarises the mechanism of oligomerisation suggested by Bernstein et al. for Aβ ().
5.02.5 Amyloid-Beta Peptide and Neurotoxicity 
Originally, the scientific community believed that the presence of amyloid fibrils, found in the senile plaques of AD patients is responsible for pathogenicity, as it is a characteristic feature of the disease. This idea was later modified as a strong correlation between the high concentration of soluble toxic Aβ oligomers and progression of the disease was discovered  ADDIN EN.CITE (; ; ; ), which suggested that the neurotoxic specie is an earlier intermediate formed during fibril formation (reviewed in ()). Using transgenic mice as a model, some studies support the notion that the neurotoxic species are plaque-independent and were present before amyloid deposition  ADDIN EN.CITE (; ; ; ). Nevertheless, other studies suggest a close relationship between plaques and neurotoxicity  ADDIN EN.CITE (; ). Although, the more toxic specie is now believed to be a prefibrillar state of Aβ, the exact assembly is difficult to study as the transient oligomeric form of Aβ peptide is in equilibrium with the monomeric and the fibrillar form of the protein. However, studies by Lambert et al. were successful in isolating the Aβ-derived diffusible ligands (ADDLs) as toxic oligomers in vitro. ADDLs were seen to kill mature neurons at nanomolar concentrations  ADDIN EN.CITE (). Walsh et al. were able to isolate human soluble Aβ oligomers, and induce the inhibition of long-term potentiation (LTP) when injected in rats (). LTP is a phenomenon which provides the measure of synaptic plasticity related to learning and memory, both areas which are affected by AD.
5.02.6 Amyloid-Beta and Prion Protein Interactions
There are many direct and indirect interactions documented for Aβ; membrane bound, intracellular proteins for example clusterin (APO J) () and apolipoprotein E (APOE) (). However, recently Laurén et al. were able to show that PrPC is the best candidate (), using unbiased screening of cDNA expression library containing 200,000 proteins. They used Aβ42 oligomers which were prepared to yield ADDLs  ADDIN EN.CITE (). The same study showed that the interaction between PrPC and Aβ42 oligomers leads to the inhibition of LTP in the hippocampal slices from normal mice, expressing PrPC. While, PrPC knockout mice had unaffected LTP, the same result was seen in mice where the PrPC-Aβ oligomer interaction was blocked. These findings, therefore, suggested that PrPC is the main receptor which mediates AD. Other receptors such as APLP1 and 30B have also been implicated, but bind with a lower affinity ().
Recently, one group used the AD transgenic mice model with the PrPC gene, PNRP, deleted, this prevented the development of functional deficits even in normal generation of Aβ and deposition in the brain (). While, a study using a different mouse model did not report any significant modulation of LTP in the presence or absence of PrPC (). The same study rules out the possibility that PrPC is the direct mediator to synaptotoxicity caused by Aβ. Like the study led by Laurén et al., those carried out by Calella et al. seem sound. The Callella paper concludes that the different effect may simply come down to which mouse model of AD is used and the effect may not be universal (). Another study, also states that no protection effect was observed in mice injected with different Aβ oligomer preparations, in the absence of PrPC (). All three studies do agree on the high affinity of PrPC for Aβ oligomers  ADDIN EN.CITE (; ; ). 
A study lead by Chen et al., using surface plasmon resonance (SPR) and side-directed spin labelling to elucidate the specific PrPC binding site for A oligomers. In addition to the crucial binding site of PrPC previously discovered, centred at residues 95-110, this study also found that the region spanning residues 23-27 is also crucial for the binding (). Like previous studies, Chen et al. also confirmed that it is Aβ oligomers, not monomeric or fibrilar, that bind PrPC (). A recent study suggested that PrPC has specific binding regions which bind Aβ40 and Aβ42 (). Zou et al. suggested that A42 specifically binds PrPC at the following areas between amino acid residues 23 to 111 and some areas of the structured C-terminus of PrPC. The specific binding sites for A​40 include the following regions: between residues 25 to 49 and 89 to 111.  Like A42 there are some areas of the C-terminus which allow the specific binding of A40.
5.02.7 Prion Protein in Alzheimer’s Disease: A Genetic Link
There is good genetic evidence to link the risk of developing sporadic AD with PrPC. A systematic meta-analyses of the genetic association of sporadic AD has made the link between AD and the PrP polymorphism at residue 129 ().  PrPC has a well-established polymorphism at M129V which is linked to the susceptibility to prion infection in vCJD and inherited Prion disease.  Importantly, genetic studies of patients suffering from sporadic AD indicate that the Met129/Met129 genotype in PrPC represents a small but significant risk factor for the disease  ADDIN EN.CITE (; ). 
Many studies have reported an early onset of cognitive dysfunction (), along with a decreased cognitive performance in the elderly for those with the Val polymorphism at position 129 in PrPC (; ). Furthermore, accelerated mental retardation in Downs Syndrome patients has been reported for those presenting with at least one Val allele, when compared to patients expressing homozygous Met at codon 129 of PrP  ADDIN EN.CITE (; ; ). 
The accumulation of globular deposits comprised of PrPC were reported in the brains of AD patients (; ) and Downs Syndrome patients (). These deposits had the ability to become stained by antibodies of Aβ and superoxide dismutase 1 enzyme, SOD1, therefore, suggesting Aβ plaques contain PrPC and SOD1 (). 
5.02.8 Aims
This chapter aims to investigate the interaction of Aβ with PrPC in particular: 
a)	The influence of full length PrPC on Aβ40 and Aβ42 fibril growth. 
b)	The isolation of PrP regions that influence Aβ fibril growth rates, using PrP fragments. 












5.03 Methods and Materials
Techniques described here are specific to this chapter, for a detailed description of the techniques and protocols used throughout the thesis, refer to chapter 2.
5.03.2 Amyloid-Beta Solubilisation
Lyophilised full length Aβ40 or Aβ42 was solubilised at 0.7 mg/mL in water (ultra-high quality, 18.2 MΩ.cm resistivity) at pH 10.5. The pH of water was adjusted using NaOH prior to the addition of Aβ. Once the sample was made, it was then left at 4 °C, while gently rocked for the duration of time between 48 to 72 hours. The pH was checked after 3 hours of incubation at 4 °C and maintained at pH 10.5. 
	After solubilisation the concentration was determined, using a Hitachi U-3010 double beam spectrophotometer, UV-Vis electronic absorption spectra were obtained using a 1 cm path-length quartz cuvette. The absorbance signal at 280 nm was measured () and extinction coefficient of 1280 M-1cm-1, for the single tyrosine (Tyr), was used to calculate the concentration of Aβ, typically, ~ 10 % of the weight was attributed to moisture. Finally, 0.5 ml aliquots of the solubilised Aβ samples, at pH 10.5, were stored at -20 °C. 
The following is a list of evidence which proves that the method of solubilisation used here produces seed free Aβ samples:
1.	There is minimal light scatter observed by UV-Vis absorbance spectroscopy.
2.	When monitored using far-UV-CD, the lack of β-sheet secondary structure is confirmed by the absence of a negative band at 217 nm, however, the Aβ samples do give rise to a band at 198 nm, which is indicative of irregular structure.
3.	The baseline levels of thioflavin T (ThT) fluorescence of the solubilised batches, indicative of a lack of fibrils present. 
4.	Gel filtration chromatography of solubilised batches shows the population is predominantly monomeric or dimeric.
5.	The long lag-phase observed in the Aβ40 and Aβ42 fibril growths (~100 hours) suggests a lack of nucleation seeds in the preparation.
2.03.3 Fibre Growth Kinetics 
The 96-well plate fluorescence reader has an excitation filter at 440 nm and an emission filter at 490 nm. Each reading consists of 50-100 flashes and agitation was optimised to 30 seconds orbital shaking every 30 minutes. Sterile flat bottomed plates were used and sealed with Starseal polyolefin sealing film. The wells hold up to 300 µL; these were used to their full capacity to reduce the volume of air in each plate. The pH of a sample is one of the critical aspects of growing fibres so it was monitored before and after each experiment. At the start of each experiment the pH was adjusted with small volumes of 10 mM NaOH and HCl and variations of ±0.05 pH units or less were observed over the course of the experiment. The fluorophore used was ThT and a stock of 2 mM was made in water and kept 5 °C away from natural light. UHQ water (10-18 Ω-1cm-1 resistivity) was used at all times.
Fibril growth kinetics are very sensitive to a number of factors that must be carefully controlled such as pH, concentration, agitation, temperature and ionic strength. Another important factor is the use of seed-free Aβ stock. The fibril growth experiments were typically carried out using 10 μM Aβ(1-40) and 5 or 10 μM Aβ(1-42) in the presence of 2 mole equivalents of ThT (i.e.10-20 μM). The sample was incubated at 30 oC in the presence of 160 mM NaCl, 50 mM HEPES buffer at pH 7.4. The concentration of NaCl used is physiologically relevant (). Figure 5.03 explains the different stages of fibril formation; this was used to describe the data produced in this chapter. Fibril growth is shown as absolute fluorescence intensity, throughout this chapter.
Fibril Growth Curve Fitting. The assembly of monomeric Aβ into fibrils undergoes three main steps shown in Figure 5.03, which essentially follows a sigmoidal curve. The initial step is the nucleation period also known as the lag phase (tlag), the next step is the fibre growth period also known as the elongation period. The final step is the equilibrium phase, where the ThT fluorescence has reached a plateau. To enable accurate comparison between fibril growth curves from different experiments each curve must be fitted with equation 1 (eq 1) ().
						(eq 1)









Figure 5.0 3: Analysis of Fibril Growth Curves






5.04.1 Influence of the Prion Protein on Amyloid-Beta Fibril Growth Kinetics 
Aβ(1-40). Here, I investigated the influence of varying amounts of PrP(23-231) on the kinetics of fibril formation of Aβ40 and Aβ42. Using the well-established amyloid binding to ThT fluorescence assay, fibre growth kinetics of Aβ have been investigated. The fibre formation of 10 µM Aβ40 alone, in Figure 5.04a, has a lag phase (tlag) period of 46 ± 3 hours. The time at which the fluorescence reaches half maximal intensity (t50) for 10 µM Aβ40 was 80 ± 4 hours. Figures 5.04b-d, show the effects of  a series of PrPC concentrations. There was no observable fibre formation of 10 µM Aβ40 in the presence of equi-molar concentration of PrPC (10 µM), as seen in Figure 5.04b. The same complete inhibition of fibre formation was observed for 0.1 mole equivalents and as little as 0.05 mole equivalents of PrP(23-231), shown in Figures 5.04c-d. One twentieth of the concentration of PrPC (50 nM) relative to Aβ40 will completely inhibit the ability of Aβ40 to form fibres. 
I was interested in finding out the smallest concentration required to stop the formation of Aβ40 fibrils. Figure 5.05 shows the ThT fibril growth assays for substoichiometric amounts of PrP(23-231). As shown previously in Figure 5.04a, the t50 of 10 µM Aβ40 fibril growth curve is 75 ± 10 hours, with a similar tlag time of 47 ± 15 hours. Again, there was no observable fibril formation of Aβ40 in the presence of 0.05 mole equivalents of PrP(23-231). In contrast, 0.025 mole equivalents of PrP(23-231) had little effect on the fibril growth of Aβ40, shown in Figure 5.05c, the average t50 is 62 ± 5 hours with a tlag period of 33 ± 5 hours. Interestingly, the final total amounts of fibres generated was also unaffected by the lower concentration of PrPC. The same is true for 0.01 mole equivalents of PrP(23-231), shown in Figure 5.05d. Fibril growth concentrations 


Figure 5.0 4: Aβ40 with PrP(23-231)






Figure 5.0 5: Aβ40 with Substoichiometric Levels of PrP(23-231)
Fibril growth curves of 10 µM Aβ40 grown in the presence and absence of substoichiometric amounts of PrP(23-231). a) Aβ40 alone. b) In the presence of 0.05 mole equivalents of PrP(23-231). c) In the presence of 0.025 mole equivalents of PrP(23-231). d) Finally, Aβ40 in the presence of 0.01 mole equivalents of PrP(23-231). All fibrils were grown at 30 ºC and at pH 7.4. At least one-twentieth of the molar concentration of PrPC is required to stop the fibril formation of Aβ40.

parameters for the data in Figure 5.05 are summarised in Table 5.01 below.
Table 5.0 1: Fibril Growth Kinetics of Aβ40 with PrPC and Fragments
	t50(hours)	tlag(hours)	kapp(hours-1)	n
10 µM Aβ40	75 ± 10	47 ± 15	0.084 ± 0.020	4
10 µM Aβ40 + 0.25 µM PrP(23-231)	62 ± 5	33 ± 5	0.072 ± 0.004	6
10 µM Aβ40 + 0.1 µM PrP(23-231)	69 ± 5	43 ± 6	0.087 ± 0.014	4
10 µM Aβ40 + 1 µM PrP(58-91)	86 ± 7	43 ± 3	0.051 ± 0.010	4
10 µM Aβ40 + 1 µM PrP(91-115)	72 ± 4	29 ± 8	0.050 ± 0.007	5
10 µM Aβ40 + 1 µM PrP(91-96)	70 ± 9	22 ± 15	0.047 ± 0.008	5
10 µM Aβ40 + 1 µM PrP(107-111)	80 ± 9	28 ± 19	0.041 ± 0.007	3
n is the number of traces used in the analysis. Errors are shown as mean standard error.
For a clearer comparison, the fibril growth curves of 10 µM Aβ40 in the presence of PrP(23-231) (data from Figure 5.05) were averaged and presented in Figure 5.06. When looking at the averaged curves, it is clear that the fibril kinetics of Aβ40 alone are similar to those produced by fibrils grown with <0.025 mole equivalents of PrPC, Figure 5.06b. All three fibril growth curves have a t50 of between 75 to 80 hours, a tlag period of 50 hours showing a similar rate of elongation, see Table 5.01. The cut-off point at which PrP(23-231) influences Aβ40 fibre growth is very pronounced, with a molar ratio of 1:20 (PrP:Aβ40) completely inhibits fibril growth, however, the molar ratio 1:40 presents no influence on the 10 μM Aβ40 fibril growth (i.e. complete inhibition at 50 nM PrP and no inhibition at 25 nM). 
Disaggregation of Pre-formed Aβ40 Fibrils. Next, the effect of PrP(23-231) on pre-formed   mature   Aβ40  fibrils   was   investigated.  Figure 5.07a  shows  the  ThT fluorescence assay of fibres at equilibrium between 230 to 260 hours of incubation, at this

Figure 5.0 6: Averaged Spectra of Aβ40 with Substoichiometric Levels of 
PrP(23-231)




Figure 5.0 7: Mature Aβ40 Fibrils with PrP(23-231) and Fragments
The effects of PrP(23-231) and fragments on mature 10 µM Aβ40 fibrils. In the presence of a) 1 mole equivalent of PrP(23-231), b) 1 mole equivalent of PrP(113-231) and c) 1 mole equivalent of PrP(90-115). The experiment was carried out at 30 ºC and at pH 7.4. Equi-molar PrPC will dissociate mature Aβ40 fibrils.
this point 10 µM of PrP(23-231) was added. The ThT signal progressively reduces in intensity, indicating that PrPC will also cause dissociation of mature Aβ40 fibrils. Almost complete loss of ThT fluorescence signal is apparent within 5 hours of PrPC addition. A parallel control experiment was carried out by adding PrP fragments; this is to see if the effect observed was not due to the interruption of the fibril growth. I monitored the effects of 10 μM PrP(113-231), Figure 5.07b, and 10 µM PrP(91-115) on mature Aβ40 fibrils, Figure 5.07c, both showed no observable decrease in the ThT fluorescence. This suggests that PrP(23-231) does not only stop Aβ40 fibril formation but will also dissociate Aβ40 mature fibrils. 




Figure 5.0 8: Aβ42 with PrP(23-231)
Fibril growth curves of 5 µM Aβ42 grown in the presence and absence of PrPC. a) Aβ42 alone. In the presence of varying amounts of PrP(23-231): b) 1 mole equivalent, c) 0.1 mole equivalents, d) 0.05 mole equivalents and finally e) 0.02 mole equivalents. All fibrils were grown at 30 ºC and at pH 7.4. 

Table 5.0 2: Fibril Growth Kinetics of 5 µM Aβ42 with PrPC and Fragments
	t50(hours)	tlag(hours)	kapp(hours-1)	n
5 µM Aβ42	115 ± 9	76 ± 14	0.078 ± 0.020	8
5 µM Aβ42 + 0.25 µM PrP(23-231)	133 ± 11	101 ± 21	0.084 ± 0.024	4
5 µM Aβ42 + 0.1 µM PrP(23-231)	90 ± 9 	41 ± 12	0.042 ± 0.005	4
n is the number of traces used in the analysis. Errors are shown as mean standard error.
I was interested to see if these observations were the same for 10 μM Aβ42. As with the Aβ42 at 5µM, the 1 mole equivalent, shown in Figure 5.09a, stops fibril formation. Under dilute conditions, 0.1 mole equivalents of PrPC almost completely stopped fibril formation; there is only a slight suggestion of fibril formation but only after a tlag of ~180 hours or more, Figure 5.09b. The presence of 0.05 mole equivalents of PrP(23-231), as for 5 μM Aβ42, delays fibril formation, and reduces the intensity, as seen in Figure 5.09c. Like the diluted Aβ42, the presence of 0.02 mole equivalents of PrPC did not stop fibril formation, Figure 5.09b. The fibrils kinetics are summarised in Table 5.03. The inhibition of fibril formation is Aβ concentration independent, as the same effects of PrPC are observed for the dilute and the concentrated Aβ42 samples.
Table 5.0 3: Fibril Growth Kinetics of 5 µM Aβ42 with PrPC and Fragments
	t50(hours)	tlag(hours)	kapp(hours-1)	N
10 µM Aβ42 + 0.5 µM PrP(23-231)	103 ± 15	69 ± 8	0.70 ± 0.014	4
10 µM Aβ40 + 0.2 µM PrP(23-231)	52 ± 5	38 ± 4	0.16 ± 0.031	3
10 µM Aβ40 + 20 µM PrP(58-91)	82 ± 9	54 ± 9	0.09 ± 0.03	3






Figure 5.0 9: Concentrated Aβ42 with PrP(23-231)
Fibril growth curves of 10 µM Aβ42 grown in the presence of PrP(23-231). a) Aβ42 alone. The following Aβ42 fibril growth conditions were prepared with varying amounts of PrPC: b) 1 mole equivalent, c) 0.1 mole equivalents, d) 0.05 mole equivalents and finally e) 0.02 mole equivalents. All fibrils were grown at 30 ºC and at pH 7.4.


5.04.2 Amyloid Beta Fibril Growth Kinetics with Prion Protein Fragments 
Aβ(1-40). Next, I wanted to investigate how different regions of PrPC influence fibre growth, whether intact full length PrPC is required for fibril inhibition or the effect is isolated to a particular region of the protein. The fibril growth kinetics were measured in the presence of a number of recombinant and synthetic peptide fragments, summarised in Figure 5.10. Fragments used included the C-terminal structured domain, the N-terminal unstructured half of PrPC and small segments of the amyloidogenic and octarepeat regions were also used.  
	Figure 5.11 shows ThT monitored fibril growth kinetic measurements for Aβ40 (10 µM) with different concentrations of PrP(91-115). Only at relatively high levels of PrP(91-115) do we observe an inhibitory effect, equi-molar ratio, while, no inhibit ion effect is observed at substoichiometric levels of the protein, a ten to one ratio (Aβ42:PrP(91-115). 
	PrP(113-231), which contains all the structured C-terminus, does not inhibit fibril growth even at 1:1 ratio. The fibril growth assay of Aβ40 with 1 mole equivalent of PrP(113-231) is shown in Figure 5.11e. In fact, PrP(113-231) may slightly accelerate fibre formation, as the tlag appears to have decreased from 46 ± 3 hours to 11 ± 8 hours the kinetics data is summarised in Table 5.04. These results suggest that the structured C-terminus of PrPC alone does not inhibit the fibril formation, therefore, ruling out this area for a direct interaction. 




Figure 5.1 0: Full PrP and Fragments Used
A representation of PrPC and its fragments that were used in the fibril growth experiments to monitor the effects they have on the Aβ40 and Aβ42 fibrils. Starting from the top: PrP(23-231) (multi-coloured), PrP(113-231) (green), PrP(23-126) (multi-coloured), PrP(58-91) (lilac), PrP(90-126) (blue), PrP(92-96) (blue) and finally PrP(107-111) (blue). The same colour codes are used to represent the main PrP fragments present found in the fibril growth assays in Figures 5.11 to 5.15.


Figure 5.1 1: Aβ40 with PrP Fragments
Fibril growth curves of 10 µM Aβ40 grown in the presence of PrP fragments. a) Aβ40 alone. The following Aβ40 fibril growth conditions were prepared with different PrP fragments: b) 1 mole equivalent of PrP(91-115), c) 0.1 mole equivalents of PrP(91-115), d) 0.05 mole equivalents of PrP(91-115) and finally e) 1 mole equivalent of PrP(113-231). All fibrils were grown at 30 ºC and at pH 7.4.
PrP(23-126), the full N-terminal fragment of PrPC, complete fibril growth inhibition is observed, Figure 5.12b. Smaller fragments of the N-terminus were used, such as 0.1 mole equivalents of PrP(58-91), the octarepeat fragment, which showed no change in the fibril formation, Figure 5.12c. The tlag and kapp observed are similar to those observed for Aβ40 alone. Fragments from the amyloidogenic region were also used, in the presence of 0.1 mole equivalents of PrP(91-115) and fibril formation was observed, Figure 5.12d, as previously discussed. The effects of the two penta-peptides from the amyloidogenic region were monitored, 0.1 mole equivalents of PrP(91-96) did not stop fibril formation and produced fibre growth curves similar to those seen for Aβ40 alone, where the nucleation period was 22 ± 15 hours with the t50 being 70 ± 9 hours, seen in Figure 5.12e and the parameters are listed in Table 5.01. A similar effect was recorded for 0.1 mole equivalents PrP(107-111), seen in Figure 5.12f.
Table 5.0 4: Fibril Growth Kinetics of Aβ40 with PrP fragments
	t50(hours)	tlag(hours)	kapp(hours-1)	n
10 µM Aβ40	80 ± 4	46 ± 3	0.059 ± 0.003	7
10 µM Aβ40 + 1 µM PrP(91-115)	70 ± 6	40 ± 8	0.071 ± 0.009	5
10 µM Aβ40 + 0.5 µM PrP(91-115)	56 ± 4	23 ± 7	0.064 ± 0.007	4
10 µM Aβ40 + 10 µM PrP(113-231)	42 ± 6	11 ± 8	0.067 ± 0.004	3
n is the number of traces used in the analysis. Errors are shown as mean standard error.
The fibril growth traces of Aβ in the presence of various fragments of PrP have been averaged and displayed in Figure 5.13, so that direct comparison under different conditions can be made. The averaged fibril growth curves clearly highlight the similarities between the fibril kinetics of Aβ40 alone and growth curves observed for 0.1 mole equivalents of different fragments from the amyloidogenic region, PrP(91-115), as 

Figure 5.1 2: Aβ40 with N-terminal PrP Fragments
Fibril growth curves of 10 µM Aβ40 grown in the presence of substoichiometric amounts of PrP fragments from the amyloidogenic and octarepeat regions. a) Aβ40 alone. The following Aβ40 fibril growth conditions were prepared with different PrP fragments: b) 0.1 mole equivalents of PrP(23-126), c) 0.1 mole equivalents of PrP(58-91), d) 0.1 mole equivalents of PrP(91-115), e) 0.1 mole equivalents of PrP(92-96) and finally f) 0.1 mole equivalents of PrP(107-111). All fibrils were grown at 30 ºC and at pH 7.4.

Figure 5.1 3: Averaged Spectra of Aβ40 with Substoichiometric Levels of PrP Fragments
Averaged fibril growth curves of 10 µM Aβ40 and substoichiometric levels of PrP fragments. a) Aβ40 alone (black), 0.1 mole equivalents of PrP(58-91) (lilac) and 0.1 mole equivalents of PrP(23-126) (pink). b) Aβ40 alone (black),  0.1 mole equivalents of PrP(91-115) (navy), 0.1 mole equivalents of PrP(107-111) (cyan) and 0.1 mole equivalents of PrP(92-96) (light cyan). All fibrils were grown at 30 ºC and at pH 7.4.

seen in Figure 5.13b. All three fibril growth curves share the same tlag of ~30 hours with a t50 of ~75 hours, seen in Table 5.02. Therefore, this suggests that the fibres formed in the presence of fragments from the amyloidogenic region of PrP are similar to those formed by 10 µM Aβ40 alone. The same is observed for 0.1 mole equivalents of the PrP(58-91)  fragment,  while   0.1  mole  equivalents  of  PrP(23-126) completely inhibits fibril formation, Figure 5.13a. Thus, ruling out an interaction between PrP(58-91) and Aβ40, this is the fragment highlighted in purple in Figure 5.10.
Aβ(1-42). The effects of various fragments of PrP on the more amyloidogenic Aβ42 was also investigated.  Figure 5.14 shows the fibril growth kinetics of Aβ42. As previously seen, 5 µM Aβ42 alone produces fibril growth curves with a t50 of 115 ± 9 hours.  Similar to Aβ40 which is unaffected by as much as 1 mole equivalent of PrP(58-91), both 5 µM and 10 µM of Aβ42 continued to produce fibrils  even in the presence of  2 mole  equivalents of  PrP(58-91), as seen in Figure 5.14b and Figure 5.15b.
	Taking together observations from Figure 5.12 to Figure 5.15, it is clear that the Aβ40 and Aβ42 fibre inhibition arises from the natively unstructured N-terminal portion of PrP(23-126). The structured C-terminal domain, residues 113-231, has no inhibitory effect on the fibril growth of Aβ40 and Aβ42. The N-terminal PrP(91-115) has an inhibitory effect but only at high concentrations relative to full length PrP.
5.04.3 Gel Filtration Chromatography of Amyloid-Beta and Prion Protein Complex
Next, the size of the Aβ40-PrPC complex formed was investigated using gel filtration chromatography. A series of samples obtained from a fibril growth assay, after 250 hour incubation time, were eluted from a Superdex 200 column, shown in Figure 5.16. The fibrils produced from 10 µM of Aβ40 showed no peaks on the chromatogram. This chocolate

Figure 5.1 4:  Aβ42 with PrP Fragments






Figure 5.1 5: Concentrated Aβ42 with PrP Fragments




Figure 5.1 6: Gel Filtration Chromatography of Aβ40 with PrP
All preparations were incubated with 10 µM Aβ40. a) And b) mature fibres, c) with 0.5 µM of PrP(23-126), d) with 0.5 µM of PrP(23-231), e) with  2 µM of PrP(23-126), and finally f) with 2 µM of PrP(23-231). Aβ40 (10 µM ) was incubated at 30 ºC and using 30 mM HEPES at pH 7.4, 160 mM NaCl and with agitation for 250 hours. The gel filtrration chromatography was carried out at 4 ºC and pH 7.4, using a Superdex 200 column. Oligomers I and II indicates the complexes formed at ~60 and ~100 kDa, respectively. 
might be expected as the fibrils formed, confirmed by ThT fibril growth assays, are far too large to come out in the range of the column, between 5 – 200 kDa, but instead elute in the void volume, as seen in the chromatogram in Figure 5.16a and b. In addition, the majority of the fibrils may not even enter the column at all.
Aβ40 was also incubated with 0.2 and 0.05 mole equivalents of PrPC, ThT fibril growth assay indicated that under these conditions no fibres were detected. The resulting chromatograms, shown in Figure 5.16f and d, have two peaks with elution volumes calibrated to 60-70 kDa (complex I) and 100-120 kDa (complex II). The extinction coefficient at 280 nm for PrP(23-231) is roughly sixty times larger than Aβ40; 62,280 and 1,280 M-1cm-1 respectively. Thus, at 10 μM Aβ40 with 2 μM PrPC the absorbance signal is dominated by PrP, in a ratio of 2 μM x 62,280 M-1cm-1: 10 μM x 1,280 M-1cm-1 (124,000:13,000). Therefore, PrPC will dominate the absorption spectra at 280 nm, strongly suggesting the Aβ40 oligomer observed must also have PrP bound. The two complexes eluting from the column at ~60 kDa and ~100 kDa, are likely to contain at least a single PrPC molecule, of 23 kDa, and Aβ40 molecules. Assuming one PrPC molecule per complex, this suggests that complex I has an oligomer size of 8 to 12 Aβ monomers (Aβ40 is 4 kDa in size) and complex II is 20 to 24 monomers in length. 
Previous studies have shown that the PrP amino acid residues required for Aβ40 binding are 95 to 110 and to a lesser extent at, the N-terminus, 23 to 27, for this reason PrP(23-126) was also studied. Fibril growth assays carried out in this thesis have shown that PrP(23-126) also inhibits Aβ fibre formation. As with PrP(23-231), PrP(23-126) formed two complexes with Aβ40 which also gave rise to two peaks of 60-70 and 100-120 kDa in size, see Figure 5.16c and e. The gel filtration chromatography suggests that the incubation of Aβ40 with either PrP(23-231) or PrP(23-126) results in the formation of two oligomeric species. The chromatogram suggests that the oligomers are approximately made of 8 to 12 (Complex I) and 20 to 24 (Complex II) monomers of Aβ40 bound to a single PrPC molecule; the smaller of the two complexes (complex I) dominates, as seen in Figure 5.16.
5.04.4 Circular Dichroism Studies of Amyloid-Beta and Prion Protein Complex
I was interested in characterising the secondary structure of the Aβ-PrP complex. The samples used were obtained from a fibril growth assay, after 250 hour incubation time. Figure 5.17a shows the far-UV-CD spectra of 10 µM Aβ40 fibrils. The spectrum indicates that the fibres are rich in β-sheet, characterised by the negative CD band at 217 nm. The same figure shows the far-UV-CD spectra of the incubated Aβ40 with PrP(23-126). It is evident that the presence of only 0.2 μM PrP(23-126) significantly reduces the β-sheet content of Aβ40 present. PrP(23-126) is a fragment from the unstructured N-terminal domain of PrPC, therefore, the resulting far-UV-CD spectra of this fragment alone has a single negative maxima at 198 nm, spectra not shown here. 




Figure 5.1 7: Far-UV-CD of Aβ40 Incubated with PrP
The secondary structure characterisation of 10 µM Aβ40 mature fibres (black) using far-UV-CD. a) 10 µM Aβ40 incubated with 0.2 µM PrP(23-126). b) 10 µM Aβ40 incubated with PrP(23-231). c) Difference spectra taken from spectra b). Inset, is a magnified spectra of the weak far-UV-CD signals from c). The samples were prepared using 160 mM NaCl, 30 mM HEPES at pH 7.4 and incubated at 30 ºC for 250 hours with agitation. 
5.04.5 Fourier Transform Infrared Studies of Amyloid-Beta and PrPC Interaction
As far-UV-CD spectra was affected by the high NaCl concentrations used in ThT fibril growth assays and some protein aggregation, hence, complimentary FT-IR studies were also performed. The samples that were tested were the product of a ThT fibril growth assay. Figures 5.18a is the FT-IR spectra of 10 μM Aβ42 mature fibres, these give rise to two peaks one characteristic of β-sheet, ~1630 cm-1, and the other of turns and β-sheet, ~1680 cm-1. This is in agreement with what is known about amyloid fibres and their structure. 
When Aβ42 is incubated in the presence of 10 μM PrP(23-126), it is evident that the β-sheet character, previously observed, has been lost, as seen in Figure 5.18b. This is in agreement with the ThT fibril growth assay, where at this ratio there were no amyloid fibres formed. The main amide-I absorption band is at 1670 cm-1 suggesting turn-like structures and perhaps some α-helical and 310-helical character. It is notable that at equi-molar ratios of 10 μM Aβ40 : 10 μM PrP(23-126) the amide-I signal will be largely the contribution from PrP(23-126), as there are more peptide bonds 42 : 103 amino acid residues, respectively. The true secondary structure of the Aβ42 oligomer maybe masked by the unordered structure of PrP(23-126). Thus, I also monitored the secondary structure of the complex at a more dilute ratio of PrP(23-126) to Aβ42, 1 to 10 respectively (103 x 1 μM : 42 x 10 μM), as seen in Figure 5.17c. At this ratio Aβ42 will dominate the amide-I stretch.
The smaller Aβ42-PrP(23-126) ratio gives an amide-I stretch with two maxima; the main absorption band gives rise to a amide-I band at ~1670 cm-1, characteristic of turns and perhaps some α-helical structure, while, the maxima at ~1630 cm-1 representative of  β-sheet structure. At the lower PrP(23-126) concentration  some         β- sheet

Figure 5.1 8: FT-IR of Aβ42 incubated PrP(23-126)
Structural characterisation using FT-IR of 10 µM Aβ42 a) mature fibres, b) with 10 µM PrP(23-126) and c) 1 µM PrP(23-126). The samples were prepared by incubating Aβ42 with 160 mM NaCl, 30 mM HEPES at pH 7.4 and 30 ºC for 250 hours with agitation.

β- sheet character is retained by Aβ. 























I show for the first time that the cellular form of the prion protein has a profound influence on both Aβ40 and Aβ42 fibril growth kinetic. Relatively small amounts of PrP(23-231) will completely inhibit fibre growth; one-tenth (100 nM) of the molar ratio of PrP will inhibit Aβ42 fibre formation, while as little as one-twentieth of the molar ratio is required to completely inhibit Aβ40 fibre formation. 
The ratio of Aβ to PrP (20 to 1) implies that the prion protein interacts with an oligomeric form of Aβ; perhaps 10 to 20 monomers in size, as a monomeric, 1:1, interaction would leave 95 % of Aβ free to form fibres. The gel filtration chromatography data suggests two Aβ-PrP complexes are formed with a molecular weight of 60 to 100 kDa in size, suggesting the Aβ oligomer bound to the prion protein is comprised of 10 to 20 monomers in size. This is in close agreement with a study by Chen et al. which suggested a binding ratio of 20 Aβ42 molecules to 1 PrPC ().
With the observation that shows the PrP promotes AD pathology, by mediating LTP dysfunction  ADDIN EN.CITE (; ), one might have expected PrPC to accelerate fibre formation of Aβ rather than inhibit it. However, oligomeric forms of Aβ are thought to be the most toxic to neurons (). My data suggests that PrPC promotes the formation of oligomeric species over fibres. Indeed, PrPC will disaggregate mature fibres suggest that PrP drives the equilibrium between the fibre and the oligomer to the oligiomeric form. PrP may therefore trap Aβ in a toxic oligomeric form.
Current literature suggest a high affinity between PrPC and synthetic Aβ42 oligomers  ADDIN EN.CITE (; ; ), placing the affinity in the nano molar region (). Low concentrations of PrPC, as low as 50 nM, will completely inhibit fibre growth of Aβ40 at 10 μM, supporting a high affinity for the interaction.
Specific Binding Region. For Aβ the use of various fragments of PrPC including the unstructured N-terminal half, residues 23-126, as well as a fragment containing the structured C-terminal domain indicates that the unstructured N-terminus is key to the Aβ-PrP interactions. In particular, I have also shown at a high enough concentration, PrP(91-115) is able to stop fibril growth. As the octa-repeats alone do not influence the binding, these observations together suggests the fibril inhibiting region is centred at residues 91 to 115 but enhanced by the N-terminal residues 23 to 58. This agrees very closely with studies mapping the binding region of PrP for Aβ oligomers which indicate the binding sites of Aβ42 and Aβ40 oligomers to PrPC mainly in the N-terminus. All groups  do  suggest  a  high  binding  affinity  of Aβ42 oligomers to parts of the N-terminal domain of PrPC, centred between residues 95 to 110  ADDIN EN.CITE (; ), and secondary binding enhancement between residues 23 to 27 (), this is in close agreement with the results shown here. These observations are also in agreement with the studies carried out by Zou et al., which linked Aβ40 to two specific binding sites in the N-terminal of PrPC centred at residues 25-49 and 89-111 ().
One study suggests a few binding sites in the C-terminus (). However, these studies used small 12 to 24 residue fragments of PrP from the C-terminus, these would be unstructured and therefore would not represent a good model of the structured domain of PrPC. Although, their studies also show specific binding sites of Aβ40 in the C-terminal region of PrPC (at residues: 129-157, 173-209 and 217-229) my results fail to show any effects caused by PrP(113-231) as fibrils continue to grow even in the presence of 1 mole equivalent.  
Possible Mechanism of PrP-A Interaction. It may be helpful to postulate the mechanism by which PrP could inhibit fibre growth. Both Lauren and Chen et al. have shown that monomeric A does not bind to PrPC  ADDIN EN.CITE (; ). The work here supports this observation in that only one-twentieth of the molar concentration of PrPC will completely inhibit fibre growth. The interaction with PrPC is very specific, centred in particular regions within PrP, ruling out multiple A monomer binding to PrPC. Thus, oligomeric A binds to PrPC. The conformational rearrangement with A upon oligomer formation must trigger recognition by PrPC. In turn, binding of the oligomer to PrPC must cap the fibre nucleating face of the oligomer and inhibit fibre growth.
Conclusion. The absence of PrPC can lead to a 50 % decrease in LTP inhibition in AD mouse model  ADDIN EN.CITE (; ), potential therapeutics could be designed that are antagonistic for the interaction of PrPC with A oligomers, in the treatment of Alzheimer’s disease. 
Fibre nucleating oligomers may have common features such as exposed hydrophobic residues in an extended -strand conformation. It has been suggested the PrPC-A recognition site may be similar to the PrPC-PrPSc interaction that induces template assisted misfolding in prion replication. Thus, this raises the possibility that AD and Prion disease share a common down-stream mechanism ().   

Future Work: Nuclear Magnetic Resonance of Amyloid Beta and Prion Protein Interaction. Preliminary studies using NMR (not shown here) and far-UV-CD were also carried out on the complex. The 2D 1H-15N HSQC NMR experiments were performed to investigate the regions of PrPC that interacts with Aβ by monitoring perturbations the chemical shifts upon Aβ addition. These experiments were carried out on various ratios of PrPC to Aβ40 monomer, the first of which was a 1:1 ratio that was monitored over the period of two days, incubated at 30ºC. However, no significant change in the 2D 1H-15N HSQC NMR spectra of PrPC was observed. At a 1:1 ratio only one-twentieth of the PrP molecules may have Aβ oligomers bound; assuming Aβ forms a twenty-mer. I repeated the experiment but this time using preformed ADDL’s and again no change in the 2D 1H-15N HSQC NMR spectra was observed. Finally, I carried out a 2D 1H-15N HSQC TROSY NMR spectra of a 1:20 ratio of PrPC to Aβ40, but unfortunately due to concentration constraints this did not produce a sufficient signal. This approach should not be ruled out, in future the formation of the complex under dilute conditions followed by a concentration step such as freeze drying or the use of membrane concentrators may prove to be helpful.


















Metal ion homeostasis has long been linked with a number of protein misfolding diseases. In particular, Cu2+ ions have been of interest due to their ability to accelerate the misfolding of proteins associated with such neurodegenerative diseases as dialysis-related amyloidosis (), Alzheimer’s disease () Parkinson’s disease (). This is interesting as the loss of Cu2+ ion homeostasis has been associated with aging, which is a strong risk factor for Prion and Alzheimer’s diseases ().
The misfolding of the prion protein (PrPC) is believed to be the key event in Prion diseases; a group of neurodegenerative diseases in mammals. In total, PrPC has six Cu2+ binding sites centered at the unstructured N-terminal domain (), where four ions are coordinated to the four eight-residue repeats (PHGGGWQ) known as the octarepeat region  ADDIN EN.CITE (; ). The two remaining Cu2+ ions are bound to the amyloidogenic region  ADDIN EN.CITE (; ; ), spanning residues 90 to 126. However, eventhough the coordination geometry and affinity of the Cu-PrP interaction are now well characterised (), the influence of Cu2+ ions on the secondary structure of PrPC is less understood.










possible that Cu2+ ions destabilise PrPC and so facilitate the protein to misfold in to the β-sheet rich infectious form, PrPSc. This opens up an avenue for clinical research and treatments as the administration of Cu2+ chelating drugs to patients suffering from Prion disease may reduce the rate of progression of the disease. There has been one study which shows that Cu2+ chelating therapy reduces Prion disease progression in mice, expressing PrP (), but more data is required in this area of research.
	There are many studies which provide sufficient evidence on the ability of PrPC to protect against oxidative damage  ADDIN EN.CITE (; ; ; ; ; ; ), while the increase in oxidative stress is thought to be a major hallmark of many neurodegenerative diseases especially Prion diseases  ADDIN EN.CITE (; ). In particular, high levels of oxidised Met residues are found in scrapie isolates (). Oxidative stress has been observed at an early pre-clinical stage of Prion disease  ADDIN EN.CITE (). I have investigated the effects of oxidation on the stability of the native fold of PrPC. The H2O2 oxidation leads to the conversion of the Met residues to MetOx. This leads to the disruption of the predominantly α-helical structured C-terminal domain within the hydrophobic core. While, Cu2+ catalysed oxidation of PrPC leads to an even more significant unfolding of the protein as His as well as the Met residues are oxidised. NMR data indicates the formation of a molten globule; again this is very interesting as it hints at the involvement of Cu2+ ions in the unfolding step of the disease progression. Results in chapter 3 and 4 not only show the involvement of Cu2+ ions in binding and oxidation but provide an avenue for drug therapy. Metal chelating in conjunction with anti-oxidant drug therapy should be considered not only in Prion diseases but other 

Figure 6.0 2: Oxidation Destabilises the Hydrophobic Core of PrPC and Generates a Molten Globule
neurodegenerative disease which display high oxidative stress levels in patients.  Anti-oxidative drug therapy has been shown to have some efficacy in prion diseases  ADDIN EN.CITE (; ; ). With significant destabilisation of the native of PrPC fold, future studies should monitor the effects of oxidation of PrPC on the rate of fibril formation. 
	Recently, there has been interest in relating Prion disease to Alzheimer's disease as they are both neurodegenerative diseases and arise from a conformational change in the proteins involved, PrP and amyloid-β (Aβ) respectively. A genetic link between the two diseases has been found, a polymorphism at codon 129 in the PrPC gene, PNRP, has been shown to affect susceptibility to Alzheimer's disease, this is dependent on whether the individual undergoes heterozygous or homozygous Met or Val expression  ADDIN EN.CITE (; ). A key report showed the requirement for PrPC for Aβ toxicity in transgenic mice models expressing the prion protein  ADDIN EN.CITE (; ). While other groups report a protective role of PrPC in Alzheimer’s disease (), however, other studies using a different transgenic mouse model, also expressing Aβ, fail to make a connection between toxicity and the presence of PrPC  ADDIN EN.CITE (; ). Although, the requirement of PrPC for Aβ toxicity is a controversial subject, all current studies do agree on a binding interaction between PrPC and Aβ peptides  ADDIN EN.CITE (; ; ).
Current studies have placed the essential recognition sites for Aβ binding to PrPC between residues 23 to 27 and more importantly residues 95 to 110 (). In this thesis I have used full length PrPC and various PrP fragments to investigate   their  effects   on  Aβ40  and   Aβ42    fibril  growth.  As   little  as  0.05  mole 

Figure 6.0 3: PrPC Inhibits Fibril Formation and Generates a Trapped Oligomer
equivalents of full length PrPC can inhibit Aβ fibril growth which suggests Aβ is trapped in an oligomer, ~80 kDa in size (20 Aβ monomers).
Further studies probing the site at which Aβ binds PrPC and the size of the oligomer formed upon the binding of the two proteins should be carried out. This is an interesting discovery and initiates many questions, such as does fibrillar or oligomeric Aβ bind PrPC in the same area as the PrPC:PrPSc interaction? If so, does PrPC bind other amyloid proteins? What is the purpose of this binding is it a protective mechanism against fibril formation or is it a destructive mechanism which “seeds” the formation of a toxic oligomer? There is much to be discovered about this protein-protein interaction, in future I would certainly like to investigate the nature of the trapped oligomer.
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